Document:

EX-10.20

 Exhibit 10.20 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 Confidential 

Execution Copy 

LICENSE AGREEMENT 

between 
 MEDIMMUNE, LLC

 and 
 VIR
BIOTECHNOLOGY, INC. 
 Dated as of September 7, 2018 

 

 TABLE OF CONTENTS 

 

							
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 GRANT OF RIGHTS
	  	 	12	 
			
	 2.1
	 	Grants to Licensee	  	 	12	 
			
	 2.2
	 	Sublicenses	  	 	13	 
			
	 2.3
	 	Retention of Rights; Limitations Applicable to License Grants	  	 	14	 
			
	 2.4
	 	MedImmune Obligations with respect to In-License Agreements	  	 	15	 
			
	 2.5
	 	Inclusion of Variants as Licensed Compounds	  	 	15	 
		
	 ARTICLE 3 DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES
	  	 	16	 
			
	 3.1
	 	Development.	  	 	16	 
			
	 3.2
	 	Commercialization.	  	 	17	 
			
	 3.3
	 	Compliance with Applicable Law	  	 	17	 
			
	 3.4
	 	Technology Transfer	  	 	17	 
			
	 3.5
	 	Manufacturing of Licensed Products	  	 	17	 
		
	 ARTICLE 4 NOMINATION OF EXCLUSIVE TARGETS FOR HLE TECHNOLOGY
	  	 	18	 
			
	 4.1
	 	Target Nomination Period	  	 	18	 
			
	 4.2
	 	Target Nomination Process	  	 	18	 
			
	 4.3
	 	Permitted Refusal	  	 	18	 
		
	 ARTICLE 5 PAYMENTS AND RECORDS
	  	 	18	 
			
	 5.1
	 	Upfront Payment	  	 	18	 
			
	 5.2
	 	Milestones	  	 	18	 
			
	 5.3
	 	Royalties	  	 	21	 
			
	 5.4
	 	Royalty Payments and Reports	  	 	22	 
			
	 5.5
	 	Mode of Payment; Offsets	  	 	22	 
			
	 5.6
	 	Taxes	  	 	22	 
			
	 5.7
	 	Interest on Late Payments	  	 	23	 
			
	 5.8
	 	Financial Records	  	 	23	 
			
	 5.9
	 	Audit Rights	  	 	23	 
			
	 5.10
	 	Audit Dispute	  	 	24	 
		
	 ARTICLE 6 INTELLECTUAL PROPERTY
	  	 	24	 
			
	 6.1
	 	Ownership of Intellectual Property	  	 	24	 

  
 i 

							
			
	 6.2
	 	Maintenance and Prosecution of Patents	  	 	25	 
			
	 6.3
	 	Patent Term Extension and Supplementary Protection Certificate	  	 	26	 
			
	 6.4
	 	Enforcement of Patents	  	 	27	 
			
	 6.5
	 	Invalidity or Unenforceability Defenses or Actions	  	 	29	 
			
	 6.6
	 	Privileged Information	  	 	30	 
		
	 ARTICLE 7 CONFIDENTIALITY AND
NON-DISCLOSURE
	  	 	30	 
			
	 7.1
	 	Confidentiality Obligations	  	 	30	 
			
	 7.2
	 	Permitted Disclosures	  	 	31	 
			
	 7.3
	 	Use of Name	  	 	31	 
			
	 7.4
	 	Public Announcements	  	 	32	 
			
	 7.5
	 	Publications	  	 	32	 
			
	 7.6
	 	Return of Confidential Information	  	 	32	 
			
	 7.7
	 	Privileged Communications	  	 	33	 
		
	 ARTICLE 8 REPRESENTATIONS AND WARRANTIES
	  	 	33	 
			
	 8.1
	 	Mutual Representations and Warranties	  	 	33	 
			
	 8.2
	 	Additional Representations and Warranties of MedImmune	  	 	34	 
			
	 8.3
	 	Additional Representations and Warranties of Licensee	  	 	35	 
			
	 8.4
	 	DISCLAIMER OF WARRANTIES	  	 	36	 
			
	 8.5
	 	ADDITIONAL WAIVER	  	 	36	 
			
	 8.6
	 	Anti-Bribery and Anti-Corruption Compliance	  	 	36	 
		
	 ARTICLE 9 INDEMNITY
	  	 	37	 
			
	 9.1
	 	Indemnification of MedImmune	  	 	37	 
			
	 9.2
	 	Indemnification of Licensee	  	 	37	 
			
	 9.3
	 	Indemnification Procedures	  	 	38	 
			
	 9.4
	 	Special, Indirect and Other Losses	  	 	39	 
			
	 9.5
	 	Insurance	  	 	40	 
		
	 ARTICLE 10 TERM AND TERMINATION
	  	 	40	 
			
	 10.1
	 	Term and Termination	  	 	40	 
			
	 10.2
	 	Termination for Convenience	  	 	40	 
			
	 10.3
	 	Termination for Material Breach	  	 	40	 
			
	 10.4
	 	Termination for Insolvency	  	 	41	 
			
	 10.5
	 	Termination for Patent Challenge	  	 	41	 
			
	 10.6
	 	Effects of Termination – General	  	 	41	 

  
 ii 

							
			
	 10.7
	 	Specific Effects of Termination; Termination by Licensee for Convenience or by MedImmune for Cause	  	 	41	 
			
	 10.8
	 	Rights in Bankruptcy	  	 	43	 
			
	 10.9
	 	Accrued Rights; Surviving Obligations	  	 	43	 
		
	 ARTICLE 11 MISCELLANEOUS
	  	 	44	 
			
	 11.1
	 	Amendment to Humabs Agreement	  	 	44	 
			
	 11.2
	 	Force Majeure	  	 	44	 
			
	 11.3
	 	Export Control	  	 	44	 
			
	 11.4
	 	Assignment	  	 	45	 
			
	 11.5
	 	Severability	  	 	45	 
			
	 11.6
	 	Dispute Resolution	  	 	45	 
			
	 11.7
	 	Governing Law and Service	  	 	47	 
			
	 11.8
	 	Notices	  	 	47	 
			
	 11.9
	 	Entire Agreement; Amendments	  	 	48	 
			
	 11.10
	 	English Language	  	 	48	 
			
	 11.11
	 	Equitable Relief	  	 	48	 
			
	 11.12
	 	Waiver and Non-Exclusion of Remedies	  	 	49	 
			
	 11.13
	 	No Benefit to Third Parties	  	 	49	 
			
	 11.14
	 	Further Assurance	  	 	49	 
			
	 11.15
	 	Relationship of the Parties	  	 	49	 
			
	 11.16
	 	References	  	 	49	 
			
	 11.17
	 	Construction	  	 	49	 
			
	 11.18
	 	Counterparts	  	 	50	 

  
 iii 

 SCHEDULES 

Schedule 1 Amendment to Humabs Agreement 
 Schedule 2
Not Used 
 Schedule 3 [***] Sequence 
 Schedule 4
[***] Sequence 
 Schedule 5 In-License Agreements 

Schedule 6 Not Used 
 Schedule 7 MedImmune Intellectual
Property 
 A. MedImmune Patents 

B. MedImmune FluAB Patents 

C. MedImmune HLE Patents 

Schedule 8 MedImmune Know-How to be transferred to Licensee 

Schedule 9 MedImmune Regulatory Documentation 
  

  
 iv 

 Confidential 

Execution Copy 

LICENSE AGREEMENT 
 This
License Agreement (the “Agreement”) is made and entered into as of September 7, 2018 (the “Effective Date”) by and between MedImmune, LLC, having a place of business at One MedImmune Way,
Gaithersburg, MD 20878, United States (“MedImmune”) and Vir Biotechnology, Inc. having a place of business at 499 Illinois Street, 5th Floor, San Francisco, CA 94158
(“Licensee”) and shall become effective on the Effective Date. MedImmune and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

Recitals 
 WHEREAS, MedImmune owns
and/or controls certain intellectual property rights with respect to the Licensed Compounds, Licensed Products, and HLE Products in the Territory (each of which is as defined herein); and 

WHEREAS, MedImmune wishes to grant, and Licensee wishes to take, a license under such intellectual property rights to develop and
commercialize Licensed Products and HLE Products in the Territory, in each case in accordance with the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 Unless otherwise specifically provided herein, the following terms shall have the following meanings: 

1.1 “Affiliate” means, with respect to a Party, any Person that, directly or indirectly, through one (1) or more
intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and “under common control with”
means: (i) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance or
otherwise; or (ii) the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general
partner or controlling entity). 
 1.2 “Agreement” has the meaning set forth in the preamble hereto. 

1.3 “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and
any other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

 1.4 “Applicable Law” means applicable laws, rules and regulations,
including any rules, regulations, guidelines having the effect of law or other requirements of the Regulatory Authorities, that may be in effect from time to time, including the FFDCA and the Anti-Corruption Laws. 

1.5 “Arbitrators” has the meaning set forth in Section 11.6(ii). 

1.6 “AstraZeneca Patent Group” means the Patent Attorney having primary responsibilities for the MedImmune Patents as of the
Effective Date. 
 1.7 “Auditor” has the meaning set forth in Section 5.9(i). 

1.8 “BPCI Act” means the Biologics Price Competition and Innovation Act of 2009, Public Law
111-148, title VII, subtitle A, as may be amended from time to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and
modifications thereto). 
 1.9 “Business Day” means a day other than a Saturday or Sunday or a day on which banking
institutions in New York, New York are permitted or required to be closed. 
 1.10 “Calendar Quarter” means each successive
period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the
first to occur of January 1, April 1, July 1 or October 1 after the Effective Date and the last Calendar Quarter shall end on the last day of the Term. 

1.11 “Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending
on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on
January 1 of the year in which the Term ends and end on the last day of the Term. 
 1.12 “Combination Product” means a
Product that is sold in the form of a combination product containing a Product and one or more other Components or ingredients (whether combined in a single formulation or package, as applicable, or formulated separately but sold together for a
single price), [***], provided that where such Component is a delivery device, such Product shall only be deemed to be a Combination Product where [***]. 

1.13 “Commercialization” means any and all activities directed to the preparation for sale of, offering for sale of or
sale of a Licensed Product, including activities related to marketing, promoting, distributing and importing such Licensed Product and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, “to
Commercialize” and “Commercializing” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

  
 2 

 1.14 “Commercially Reasonable Efforts” means, with respect to the
performance of Development, Commercialization, Manufacturing or other activities specified hereunder by a Party, [***]. 
 1.15
“Component” means [***]. 
 1.16 “Compulsory License” means, with respect to a country, a compulsory
sublicense under the MedImmune Intellectual Property obtained by a Third Party through the order, decree or grant of a governmental authority in such country, authorizing such Third Party to Develop, manufacture or Commercialize a Product in the
Field in such country. 
 1.17 “Confidential Information” has the meaning set forth in Section 7.1. 

1.18 “Control” means, with respect to any item of Know-How, Regulatory
Documentation, material, Patent or other intellectual property right, possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation of the license and other grants in
Section 2.1), to grant a license, sublicense or other right (including the right to reference Regulatory Documentation) to or under such Know-How, Regulatory Documentation, material, Patent or other
intellectual property right as provided for herein without violating the terms of any agreement with any Third Party. 
 1.19
“Controlling Party” has the meaning set forth in Section 6.5(iii). 
 1.20 “Cover” means, with respect
to a Patent and a product, such Patent would (absent a license thereunder or ownership thereof) be infringed by the manufacture, use, offer for sale or sale of such product, provided, however, that in determining whether a claim of a pending Patent
application would be infringed, it shall be treated as if issued in the form then currently being prosecuted. Cognates of the word “Cover” shall have correlative meanings. 

1.21 “Development” means all activities related to research, pre-clinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing scale-up, qualification and validation,
quality assurance/quality control, clinical studies, including Manufacturing in support thereof, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing
and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval. When used as a verb, “Develop”
means to engage in Development. 
 1.22 “Direct Competitor” means a Third Party developing and/or commercializing a product
[***] other than a Licensed Compound or Licensed Product being developed pursuant to a sublicence from Licensee. 
 1.23
“Dispute” has the meaning set forth in Section 11.6(i). 
 1.24 “Dispute Auditor” has
the meaning set forth in Section 5.10. 

  
 3 

 1.25 “Dollars” or “$” means United States Dollars. 

1.26 “Drug Approval Application” means (i) a Biologic License Application as defined in 21 CFR 601.2 or any corresponding
foreign application in the Territory, including, with respect to the European Union, (ii) a Marketing Authorization Application filed with the EMA pursuant to the centralized approval procedure or with the applicable Regulatory Authority of a
country in Europe, and (iii) any other application filed with the applicable Regulatory Authority for the approval to market a Product in the applicable jurisdiction. 

1.27 “Effective Date” has the meaning set forth in the preamble hereto. 

1.28 “EMA” means the European Medicines Agency and any successor agency thereto. 

1.29 “Enforcing Party” has the meaning set forth in Section 6.4(ii)(b). 

1.30 “European Union” or “EU” means the economic, scientific and political organization of member states as
it is constituted as of the Effective Date and as it may be expanded or contracted from time to time after the Effective Date. For purposes of Section 5.2(i), “EU” refers to the EU as it is constituted at the time the applicable
milestone event is achieved. 
 1.31 “Excluded Sequences” means [***]. 

1.32 “Exclusive Target” has the meaning set forth in Section 4.1. 

1.33 “Exploit” means to make, have made, import, use, sell or offer for sale, including to research, Develop, commercialize,
register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market or have sold or otherwise dispose of. “Exploitation” means the act of
Exploiting a compound, product or process. 
 1.34 “[***]” means [***]. The molecule [***] is not itself a Flu B Compound.

 1.35 “[***]” means [***] as set forth in Schedule 3. 

1.36 “FDA” means the United States Food and Drug Administration and any successor agency thereto. 

1.37 “FFDCA” means the United States Food, Drug, and Cosmetic Act, as amended from time to time, together with any
rules, regulations and requirements promulgated thereunder (including all additions, supplements, amendments, extensions and modifications thereto). 

1.38 “Field” means (a) for the purposes of a Licensed Compound and a Licensed Product, all uses in humans or animals
(including but not limited to prophylactic and therapeutic treatment as well as diagnosis of human or animal diseases, disorders or conditions); and (b) for the purposes of an HLE Product, all uses in humans or animals for the prevention,
treatment, and/or diagnosis of infectious diseases. 

  
 4 

 1.39 “First Commercial Sale” means, with respect to a Product and a
country, the first sale by Licensee, its Affiliates or its Sublicensees for monetary value for use or consumption by the end user of such Product in such country after Regulatory Approval for such Product has been obtained in such country. 

1.40 “Flu A Compound” means a monoclonal antibody (i) that is [***]; (ii) that [***] or (b) that is a Variant
that has been designated as a Flu A Compound by Licensee in accordance with Section 2.5(iii); and (iii) that has been engineered to extend the antibody’s half-life by [***]. A Flu A Compound may [***]. The molecule [***] whether
delivered as an antibody or a modified or unmodified polynucleotide encoding the same, is not itself a Flu A Compound. A Flu A Compound may be delivered as an antibody or a modified or unmodified polynucleotide encoding the same. 

1.41 “Flu A Product” means any product that constitutes, is comprised of or contains a Flu A Compound in any and all
forms, presentations, dosages and formulations. 
 1.42 “Flu B Compound” means a monoclonal antibody (i) that is
[***]; (ii) that [***] or (b) that is a Variant that has been designated as a Flu B Compound by Licensee in accordance with Section 2.5(iii); and (iii) that has been engineered to extend the antibody’s half-life by [***]. A Flu B
Compound may [***]. The molecule [***] whether delivered as an antibody or a modified or unmodified polynucleotide encoding the same, is not itself a Flu B Compound. A Flu B Compound may be delivered as an antibody or a modified or unmodified
polynucleotide encoding the same. 
 1.43 “Flu B Product” means any product that constitutes, is comprised of or
contains a Flu B Compound in any and all forms, presentations, dosages and formulations. 
 1.44 “GAAP” means, with
respect to a Party or its Affiliates or its or their sublicensees, United States generally accepted accounting principles, International Financial Reporting Standards or such other similar national standards as such Party, Affiliates or its or their
sublicense adopts, in each case, consistently applied. 
 1.45 “GLP” means Good Laboratory Practice as defined in 21 CFR
Part 58. 
 1.46 “Government Official” means (i) any Person employed by or acting on behalf of a government,
government-controlled agency or entity or public international organization, (ii) any political party, party official or candidate, (iii) any Person who holds or performs the duties of an appointment, office or position created by custom
or convention or (iv) any Person who holds himself out to be the authorized intermediary of any of the foregoing. 
 1.47
“HLE Product” means an antibody or other immunoglobulin molecule binding to an Exclusive Target and which has been modified to extend the half-life of the antibody or other immunoglobulin molecule [***]. 

1.48 “Humabs” means Humabs BioMed SA, which, as of the Effective Date, is a wholly owned subsidiary of Licensee. 

  
 5 

 1.49 “Humabs Agreement” means the agreement executed between MedImmune and
Humabs dated 20 March 2012, as amended, for a license granted from Humabs to MedImmune to Exploit influenza monoclonal antibodies. 

1.50 “Improvements” means any invention, discovery, development or modification with respect to the Licensed Compound or a
Licensed Product or relating to the Exploitation thereof, whether or not patented or patentable, including any enhancement in the efficiency, operation, Manufacture, ingredients, preparation, presentation, formulation, means of delivery or dosage of
such Licensed Compound or Licensed Product, any discovery or development of any new or expanded indications for such Licensed Compound or Licensed Product, or any discovery or development that improves the stability, safety or efficacy of such
Licensed Compound or Licensed Product. 
 1.51 “IND” means (i) an investigational new drug application filed with the
FDA for authorization to commence clinical studies and its equivalent in other countries or regulatory jurisdictions and (ii) all supplements and amendments that may be filed with respect to the foregoing. 

1.52 “Indemnification Claim Notice” has the meaning set forth in Section 9.3(i). 

1.53 “Indemnified Party” has the meaning set forth in Section 9.3(i). 

1.54 “Indirect Tax(es)” has the meaning set forth in Section 5.6(ii). 

1.55 “Infringement” has the meaning set forth in Section 6.4(i). 

1.56 “Initiation” means, with respect to a clinical study, the first dosing of the first human subject in such clinical study.

 1.57 “In-License Agreement” means any license or other agreement entered into
prior to the Effective Date by and between MedImmune or any of its Affiliates, on the one hand and one (1) or more Third Parties, on the other hand, listed in Schedule 5, as such license or other agreement may be amended from time to
time during the Term. 
 1.58 “Invoiced Sales” has the meaning set forth in the definition of “Net Sales.”

 1.59 “Know-How” means all technical tangible and intangible techniques,
information, technology, practices, formulae, trade secrets, inventions (whether patentable or not), methods, processes, procedures, ideas, technical assistance, knowledge, know-how, conclusions, instructions,
designs, drawings, assembly procedures, computer programs, apparatuses, specifications, skill, experience, data and results (including biological, chemical, physical, pharmacological, toxicological, safety, manufacturing, pre-clinical and clinical test data and results), Regulatory Documentation, analytical and quality control data, results or descriptions, software and algorithms, and materials, including biological materials, cell
lines, compositions and the like. Know-How does not include (i) issued Patents, (ii) Trademarks or (ii) commercial marketing information. 

  
 6 

 1.61 “Knowledge” means [***]. 

1.62 “Licensed Compound” means a Flu A Compound or a Flu B Compound, as applicable. 

1.63 “Licensed Product” means a Flu A Product, a Flu B Product or a product that contains both a Flu A Product and a Flu B
Product, as applicable. 
 1.64 “Licensee” has the meaning set forth in the preamble hereto. 

1.65 “Licensee Intellectual Property” means all Improvements Controlled by Licensee or its Affiliates that are/is used,
generated or conceived during the Term by Licensee or its Affiliates and necessary or useful for the Exploitation of a Licensed Compound and/or Licensed Product. 

1.66 “Licensee Records” has the meaning set forth in Section 5.8. 

1.67 “Licensee Representatives” has the meaning set forth in Section 8.6. 

1.68 “Losses” has the meaning set forth in Section 9.1. 

1.69 “Major Markets” means the United States, [***]. 

1.70 “Manufacture” and “Manufacturing” means all activities related to the production, manufacture,
processing, filling, finishing, packaging, labeling, shipping and holding of a product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and quality control. 

1.71 “Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to the subject matter of
this Agreement that would, if it were publicly known, in the reasonable view of Licensee, have a material adverse effect on MedImmune or on the reputation of MedImmune because of its relationship with Licensee. 

1.72 “[***]” means [***]. 

1.73 “[***]” means [***] as set forth in Schedule 4. 

1.74 “MedImmune” has the meaning set forth in the preamble hereto. 

1.75 “MedImmune FluAB Patents” means (i) the Patents set forth in Schedule 7(B); (ii) any Patent filed after the
Effective Date claiming priority to any Patent set forth in Schedule 7(B), solely to the extent the claims thereof Cover a Licensed Compound or Licensed Product, and (iii) any counterparts of a Patent described in subclause (i) filed with
patent agencies in other jurisdictions following the Effective Date, solely to the extent the claims thereof Cover a Licensed Compound or Licensed Product. Upon request of the Licensee, the Parties shall update Schedule 7(B) in writing from time-to-time to reflect the then-current list of MedImmune FluAB Patents. 

  
 7 

 1.76 “MedImmune HLE Patents” means (i) the
Patents set forth in Schedule 7(C); (ii) any Patent filed after the Effective Date claiming priority to any Patent set forth in Schedule 7(C), solely to the extent the claims thereof Cover an HLE Product, and (iii) any counterparts of a Patent
described in subclause (ii) filed with patent agencies in other jurisdictions following the Effective Date, solely to the extent the claims thereof Cover an HLE Product. Upon request of the Licensee, the Parties shall update Schedule 7(C) in
writing from time-to-time to reflect the then-current list of MedImmune HLE Patents. 

1.77 “MedImmune Intellectual Property” means the MedImmune Patents, the MedImmune
Know-How and the MedImmune HLE Patents and the MedImmune FluAB Patents. 
 1.78 “MedImmune Know-How” means all of the Know-How Controlled by MedImmune or any of its Affiliates as of the Effective Date or during the Term for the Exploitation of a Licensed
Compound or Product as set forth in Schedule 8. MedImmune Know-How includes the MedImmune Regulatory Documentation  

1.79 “MedImmune Patents” means (i) the Patents set forth in Schedule 7(A); (ii) any Patent filed after the Effective Date
claiming priority to any Patent set forth in Schedule 7(A), solely to the extent the claims thereof Cover a Licensed Compound or Licensed Product, and (iii) any counterparts of a Patent described in subclause (ii) filed with patent
agencies in other jurisdictions following the Effective Date, solely to the extent the claims thereof Cover a Licensed Compound or Licensed Product. For the avoidance of doubt, MedImmune Patents exclude the MedImmune HLE Patents and MedImmune FluAB
Patents. Upon request of the Licensee, the Parties shall update Schedule 7(A) in writing from time-to-time to reflect the then-current list of MedImmune Patents. 

1.80 “MedImmune Regulatory Documentation” means the Regulatory Documentation Controlled by MedImmune or its Affiliates
existing as of the Effective Date and listed on Schedule 9. 
 1.81 “Necessary” means [***]. 

1.82 “Net Sales” means, with respect to a Product for any period, the gross amount billed or invoiced by Licensee, its
Affiliates or its or their Sublicensees (each, a “Selling Party”) to Third Parties for the sale of such Product (the “Invoiced Sales”), less deductions for: [***]. 

Any of the deductions listed above that involves a payment by Licensee, its Affiliates or its or their Sublicensees shall be taken as a
deduction in the Calendar Quarter in which the payment is accrued by such entity. For purposes of determining Net Sales, a Product shall be deemed to be sold when invoiced and a “sale” shall not include transfers or dispositions of such
Product for pre-clinical or clinical purposes or as samples, in each case, without charge, Licensee’s, its Affiliates’ or its or their Sublicensees’ transfer of any Product to an Affiliate or
Sublicensee shall not result in any Net Sales, unless such Product is consumed or administered by such Affiliate or Sublicensee in the course of its commercial activities. [***]. 

  
 8 

 [***]. 

[***]. 
 Subject to the above, Net
Sales shall be calculated in accordance with the standard internal policies and procedures of Licensee, its Affiliates or its or their Sublicensees, which must be in accordance with GAAP. 

1.83 “Party” and “Parties” have the meaning set forth in the preamble hereto. 

1.84 “Patents” means: (i) all national, regional and international patents and patent applications, including provisional
patent applications; (ii) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (iii) any and all patents that have issued or in the future issue from
the foregoing patent applications ((i) and (ii)), including utility models, petty patents, innovation patents and design patents and certificates of invention; (iv) any and all extensions or restorations by existing or future extension or
restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or patent applications
((i), (ii) and (iii)); and (v) any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or patent of
additions to any of such foregoing patent applications and patents. 
 1.85 “Patent Challenge” has the meaning set forth in
Section 10.5. 
 1.86 “Payment” has the meaning set forth in Section 5.6(i). 

1.87 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency
of a government. 
 1.88 “Phase 1 Study” means that portion of the drug development and review process which
provides for the initial introduction of an investigational new drug into humans in any country that would satisfy the requirements of 21 C.F.R 312.21(a) (FDCA), as amended from time to time, and the ex-US
national equivalent thereof. 
 1.89 “Phase 2 Study” means that portion of the drug development and review process which
provides for early controlled clinical studies conducted to obtain preliminary data on effectiveness of an investigational new drug for a particular indication, in any country that would satisfy the requirements of 21 C.F.R 312.21(b) (FDCA), as
amended from time to time, and the ex-US national equivalent thereof. 

  
 9 

 1.90 “Phase 3 Study” means that portion of the drug development and review
process in which expanded clinical studies are conducted to gather the additional information about effectiveness and safety that is required to evaluate the overall benefit-risk relationship of an investigational new drug, in any country that would
satisfy the requirements of 21 C.F.R 312.21(c) (FDCA), as amended from time to time, and the ex-US national equivalent thereof. 

1.91 “Prior CDA” means that certain Confidential Disclosure Agreement by and between the Parties, dated [***], as amended on
[***]. 
 1.92 “Product” means a Licensed Product or an HLE Product, as applicable. 

1.93 “Prosecuting Party” has the meaning set forth in Section 6.2(i)(b). 

1.94 “Registrational Clinical Trial” means a clinical trial in humans of a product performed to gain evidence with statistical
significance of the efficacy of such product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for Regulatory
Approval by a Regulatory Authority and to provide an adequate basis for physician labeling, as described in 21 C.F.R. 312.21(c), as amended from time to time, or the corresponding regulations in jurisdictions other than the United States whether or
not such clinical trial results in a filing for Regulatory Approval. Any clinical trial conducted under a protocol which identifies such trial as a “Phase 3” or “pivotal” trial shall be deemed to be a Registration Study. Any
clinical trial conducted under a protocol which identifies such trial as a “Phase 2/3” trial shall be deemed to be a Registration Study upon dosing of the first patient in the Phase 3 portion of such trial (which shall also be deemed to be
the Initiation of such Registration Study). 
 1.95 “Regulatory Approval” means, with respect to a country in the Territory,
any and all approvals (including approvals of Drug Approval Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country, including, where
applicable, (i) pricing or reimbursement approval in such country, (ii) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related
thereto) and (iii) labeling approval. 
 1.96 “Regulatory Authority” means any applicable supra-national, federal,
national, regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of Licensed Compound or
Products in the Territory, including the FDA in the United States and the EMA in the European Union. 
 1.97 “Regulatory
Documentation” means: all (i) applications (including all INDs and Drug Approval Applications), registrations, licenses, authorizations and approvals (including Regulatory Approvals); (ii) correspondence and reports submitted to
or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint
files; and (iii) clinical and other data contained or relied upon in any of the foregoing; in each case ((i), (ii) and (iii)) relating to the Licensed Compound or a Product. 

  
 10 

 1.98 “Regulatory Exclusivity Period” means, with respect to each Product in
any country in the Territory, any period of data, market or other regulatory exclusivity (other than Patent exclusivity) granted or afforded by Applicable Law or by a Regulatory Authority in such country that confers exclusive marketing rights with
respect to such Product in such country or prevents another party from using or otherwise relying on any data supporting the approval of the applicable Drug Approval Application. 

1.99 “Retained Rights” mean, the rights of MedImmune, its Affiliates and its and their licensors, (sub)licensees and
contractors to (i) perform its and their obligations under this Agreement; and (ii) develop, obtain and maintain regulatory approvals for and to Manufacture, commercialize and otherwise Exploit any monoclonal antibody or product [***], but
not any Licensed Compound or Product, in any field (including the Field) anywhere in the Territory. 
 1.100 “Royalty Term”
means, with respect to each Product and each country in the Territory, the period beginning on the date of the First Commercial Sale of such Product in such country and ending on the latest to occur of: (i) the expiration of the last-to-expire Patent that contains a Valid Claim Covering a Product in such country; (ii) the expiration of Regulatory Exclusivity Period in such country for such
Product; and (iii) the twelfth (12th) anniversary of the First Commercial Sale of such Product in such country. 
 1.101 “Senior
Officer” means, with respect to MedImmune, [***] and with respect to Licensee, [***]. 
 1.102 “Skipped Flu A
Milestone” has the meaning set forth in Section 5.2(ii). 
 1.103 “Skipped Flu B Milestone” has the meaning
set forth in Section 5.2(iv). 
 1.104 “Sublicensee” means a Person, other than an Affiliate, that is granted a
sublicense by Licensee or its Affiliate under the grants in Section 2.1, as provided in Section 2.2. 
 1.105
“Target” means [***]. 
 1.106 “Term” has the meaning set forth in Section 10.1. 

1.107 “Territory” means the entire world. 

1.108 “Third Party” means any Person other than MedImmune, Licensee and their respective Affiliates. 

1.109 “Third Party Claims” has the meaning set forth in Section 9.1. 

1.110 “Trademark” means any word, name, symbol, color, shape, designation or any combination thereof, including any
trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration rights, program name, delivery form name, certification mark, collective mark, logo, tagline, slogan, design
or business symbol, that functions as an identifier of source, origin or quality, whether or not registered, and all statutory and common law rights therein and all registrations and applications therefor, together with all goodwill associated with,
or symbolized by, any of the foregoing. 

  
 11 

 1.111 “United States” or “US” means the United States of
America and its territories and possessions (including the District of Columbia and Puerto Rico). 
 1.112 “Valid Claim”
means (i) a claim of any issued and unexpired Patent whose validity, enforceability or patentability has not been affected by (a) irretrievable lapse, abandonment, revocation, dedication to the public or disclaimer or (b) a holding,
finding or decision of invalidity, unenforceability or non-patentability by a court, governmental agency, national or regional patent office or other appropriate body that has competent jurisdiction, such
holding, finding or decision being final and unappealable or unappealed within the time allowed for appeal or (ii) a claim of a pending Patent application that was filed and is being prosecuted in good faith and has not been (a) [***], (b)
abandoned or (c) finally disallowed without the possibility of appeal or re-filing of the application; provided, however, that in the case of (ii)(a), if, thereafter, a patent containing such claim
issues, such claim shall thereafter be considered a Valid Claim in accordance with subclause (i) above. 
 1.113
“Variant” means a monoclonal antibody (a) (1) that [***] and that otherwise meets the definition of a Flu A Compound; or (2) that [***] and that otherwise meets the definition of a Flu B Compound, and (b) has been
selected by Licensee and approved by MedImmune in accordance with Section 2.5(i). 
 ARTICLE 2 

GRANT OF RIGHTS 
 2.1
Grants to Licensee. Subject to Sections 2.2 and 2.3 and the other terms and conditions of this Agreement: 
 (i) MedImmune
hereby grants to Licensee a non-exclusive license (or sublicense, as applicable), with the right to grant sublicenses in accordance with Section 2.2, under the MedImmune Intellectual Property to generate,
research and optimize Variants; 
 (ii) Medimmune hereby grants to licensee an exclusive (including with regard to MedImmune and its
Affiliates) license (or sublicense), with the right to grant sublicenses in accordance with Section 2.2, under the MedImmune Intellectual Property to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory;

 (iii) MedImmune hereby grants to Licensee a non-exclusive license (or sublicense) under the
MedImmune FluAB Patents to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory with the right to sublicense as set out in Section 2.2. 

(iv) MedImmune hereby grants to Licensee an exclusive license on a
Target-by-Target basis, (including with regard to MedImmune and its Affiliates) under the MedImmune HLE Patents to Exploit HLE Products directed against up to two
(2) Targets in the Field in the Territory, with the right to sublicense as set out in Section 2.2. [***]. Licensee may nominate Exclusive Targets in accordance with Article 4. For the avoidance of doubt (as and set forth in
Section 2.2(ii) and 2.3(ii)), such license is subject always to the limitations on exclusivity, if any, set forth in the applicable In-License Agreement; and 

  
 12 

 (v) MedImmune hereby grants to Licensee the right to access, reference and utilize
[***] MedImmune Know-How, in connection with Development and Manufacturing related to [***]. 
 For the avoidance of
doubt, the MedImmune HLE Patents licensed under this Section 2.1 are licensed to Licensee only to the extent of extending the half-life of the antibody or other immunoglobulin molecule [***]. 

2.2 Sublicenses. Licensee shall have the right to grant sublicenses (or further rights of reference), under the licenses and
rights of reference granted in Section 2.1 as follows: 
 (i) With respect to the rights granted in Section 2.1(ii), to its
Affiliates and other Persons: provided that any such sublicenses shall be (a) subject to the prior written consent of any applicable Third Party licensor only if and to the extent such consent is required under the applicable In-License Agreement, and (b) consistent with, and expressly made subject to, the terms and conditions of this Agreement and the In-License Agreements, Licensee shall
cause each Sublicensee to comply with the applicable terms and conditions of this Agreement and the In-License Agreements, as if such Sublicensee were a Party to this Agreement. 

(ii) With respect to the rights granted in Section 2.1(iv), Licensee shall have the right to grant a sublicense to MedImmune HLE
Patents only in connection with a license to an HLE Product; provided that any such sublicenses shall be (a) subject to the prior written consent of any applicable Third Party licensor only if and to the extent such consent is
required under any applicable In-License Agreement and (b) consistent with, and expressly made subject to, the terms and conditions of this Agreement and the
In-License Agreements, Licensee shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement and the In-License Agreements, as if
such Sublicensee were a Party to this Agreement. Licensee has no rights to sublicense the MedImmune HLE Patents rights alone. 
 (iii)
With respect to the rights granted in Section 2.1(iii), Licensee shall have the right to grant a sublicense to MedImmune FluAB Patents only in connection with a license to a Flu A Product or a Flu B Product Licensee shall cause each
Sublicensee to comply with the applicable terms and conditions of this Agreement as if such Sublicensee were a Party to this Agreement. Licensee has no rights to sublicense the MedImmune FluAB Patents rights alone. 

(iv) Licensee hereby (a) guarantees the performance of its Affiliates and Sublicensees that are sublicensed as permitted herein and
the grant of any such sublicense shall not relieve Licensee of its obligations under this Agreement, except to the extent they are satisfactorily performed by such Sublicensee and (b) waives any requirement that MedImmune exhaust any right,
power or remedy, or proceed against any Sublicensee for any obligation or performance under this Agreement prior to proceeding directly against Licensee. 

  
 13 

 (v) A copy of any sublicense agreement executed by Licensee shall be provided to
MedImmune within [***] after its execution; [***]. Notwithstanding the foregoing, Licensee shall not be required to provide copies of any service agreement containing a sublicense of rights hereunder where such sublicense is solely for the
provision of services to Licensee, its Affiliates or its Sublicensees. 
 (vi) Licensee and its Affiliates shall [***], except in
accordance with subsection (vii) below. The foregoing shall [***]. 
 (vii) Licensee and its Affiliates acknowledge that [***] in
accordance with this subsection (vii). Each sublicense agreement hereunder (other than to a Sublicensee that is a service provider described in the second sentence of subsection (v) above that is providing services to Licensee or any of its
Affiliates) will contain provisions [***]. 
 2.3 Retention of Rights; Limitations Applicable to License Grants. 

(i) Retained Rights of MedImmune. Notwithstanding anything to the contrary in this Agreement and without limitation of any rights
granted or reserved to MedImmune pursuant to any other term or condition of this Agreement, MedImmune hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its licensors, (sub)licensees and contractors) all right, title
and interest in and to the MedImmune Intellectual Property and the MedImmune Regulatory Documentation with respect to performing or exercising the Retained Rights. For clarity, MedImmune shall have no right to use any Licensee Intellectual Property,
Licensee Confidential Information or any other Patent or Know-How Controlled by Licensee or its Affiliates (excluding the MedImmune Intellectual Property) in connection with performing or exercising the
Retained Rights. 
 (ii) In-License Agreements. The licenses granted by MedImmune in
Section 2.1 include sublicenses under the applicable license rights granted to MedImmune by Third Parties under the In-License Agreements (but no other sublicense rights), subject to this Section (ii).
Any sublicense with respect to Know-How or other intellectual property rights of a Third Party hereunder and any right of Licensee (if any) to grant a further sublicense thereunder, shall be subject and
subordinate to the terms and conditions of the In-License Agreement under which such sublicense is granted and shall be effective solely to the extent permitted under the terms of such agreement. Without
limitation of the foregoing, in the event and to the extent that any In-License Agreement requires that particular terms or conditions of such In-License Agreement be
contained or incorporated in any agreement granting a sublicense thereunder, such terms and conditions are hereby deemed to be incorporated herein by reference and made applicable to the sublicense granted herein under such In-License Agreement. 
 (iii) Reservation of Rights. No rights, other than those expressly set
forth in this Agreement are granted to either Party hereunder, and no additional rights shall be deemed granted to either Party by implication, estoppel or otherwise, with respect to any intellectual property rights. All rights not expressly granted
by either Party or its Affiliates to the other Party hereunder are reserved. Neither Party shall use the Confidential Information of the other Party for any purpose except as contemplated under this Agreement. 

  
 14 

 2.4 MedImmune Obligations with respect to
In-License Agreements. MedImmune shall, and, if applicable, shall cause its Affiliates to, while Licensee has a license hereunder to any Patent or Know-How that are
subject to an In-License Agreement: 
 (i) maintain such
In-License Agreement in full force and effect and not terminate such In-License Agreement, except with Licensee’s prior written approval, which shall not be
unreasonably withheld, conditioned or delayed; 
 (ii) not amend or waive, or take any action or omit to take any action that would
alter, any of MedImmune’s or such Affiliate’s rights under such In-License Agreement in any manner that would materially adversely affects or would reasonably be expected to materially adversely
affect, Licensee’s rights under this Agreement, in each case without Licensee’s prior written approval, which shall not be unreasonably withheld, conditioned or delayed. If Licensee provides such approval, then MedImmune shall provide
Licensee with a true and accurate copy of any such amendment or waiver promptly following its execution; provided that the terms of any such amendment to the extent not pertinent to an understanding of a Party’s obligations or benefits
under this Agreement may be redacted; 
 (iii) timely make any payments due to the counterparty to such
In-License Agreement, other than payments due to Humabs from Licensee in accordance with Section 5.3(iii); and 

(iv) promptly notify Licensee in writing of the receipt or delivery of any notice of any termination or amendment of any such In-License Agreement. 
 2.5 Inclusion of Variants as Licensed Compounds. 

(i) Nomination Process. Licensee may nominate potential Variants for use under the license set forth in Section 2.1(i), as set
forth herein. [***] may be included under this Agreement, as applicable at any given moment in time. Licensee may notify MedImmune in writing from time-to-time of such
proposed Variant(s) and the sequence thereof. MedImmune will have [***] to respond to such notification as to whether each proposed Variant requested is available for inclusion in Licensee’s exclusive license under Section 2.1(ii). If such
proposed Variant is not subject to a permitted refusal pursuant to subsection (ii) below, then MedImmune shall notify Licensee that such proposed Variant is available and as of the date of Licensee’s receipt of such notice, such proposed
Variant shall thereafter be deemed to be a Variant hereunder, subject to Licensee’s right to thereafter withdraw such Variant from this Agreement by written notice to MedImmune (in which event such antibody shall cease to be deemed a Variant
hereunder upon MedImmune’s receipt of such notice). 
 (ii) Permitted Refusal. MedImmune may refuse the request for a proposed
Variant to become a Variant only in the following circumstances: [***]. 
 (iii) Development of Compounds. Licensee may designate a
maximum of two (2) Variants as Flu A Compound(s) and two (2) Variants as Flu B Compound(s) (as applicable) to progress into Development. Such designation for a Variant shall occur [***]. These Variants so designated will become the
Licensed Compounds hereunder as of the date of MedImmune’s receipt of Licensee’s notice of designation and on the date the second Flu A and/or the Flu B Compound is designated the license granted under Section 2.1(i) to all other
Variants (as they apply to the Flu A or Flu B Compound respectively) expires. 

  
 15 

 ARTICLE 3 

DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES 

3.1 Development. 
 (i)
Diligence. After the Effective Date, subject to the Retained Rights, as between the Parties, Licensee shall be solely responsible for all aspects of the Development of the Licensed Compound(s) and Licensed Products and HLE Products in the Field
in the Territory. Without limitation of Section 3.1(ii), Licensee shall use Commercially Reasonable Efforts to Develop, and obtain and maintain Regulatory Approvals for, at least one Flu A Product and at least one Flu B Product and at least one
HLE Product for each target for which an Exclusive Target license has been granted in the Field in the Major Markets. Licensee shall have the right but not the obligation to use the HLE Technology in the Exploitation of the Licensed Compound
and the Licensed Product(s). For clarity, Licensee shall have no obligations under this Section 3.1(i) with respect to any HLE Product unless and until at least one Target has been deemed to be an Exclusive Target in accordance with Article 4.

 (ii) Development Costs. Licensee shall be responsible for all of its costs and expenses in connection with the Development of, and
obtaining and maintaining Regulatory Approvals for, the Products in the Field in the Territory. 
 (iii) Development Records. Licensee
shall, and shall cause its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records pertaining to Development of Products hereunder, in sufficient detail to verify compliance with its
obligations under this Agreement. Such books and records shall (a) be appropriate for patent and regulatory purposes, (b) be in compliance with Applicable Law, (c) reflect all work done and results achieved in the performance of its
Development activities hereunder in accordance with good scientific practices, and (d) be retained by Licensee for such period as may be required by Applicable Law. 

(iv) Development Reports. Without limiting Section 3.1(iii), within [***] during which Licensee is conducting Development
activities hereunder until the time of First Commercial Sale of each type of Product (i.e., a Flu A Product, Flu B Product or HLE Product) Licensee shall provide MedImmune with a detailed written report of such Development activities it has
performed, or caused to be performed, since the preceding report with respect to each such type of Product. Each such report shall contain sufficient detail to enable MedImmune to assess Licensee’s compliance with its obligations under
Section 3.1(i). For clarity, Licensee shall have no obligations under this Section 3.1(iv) with respect to any HLE Product unless and until at least one Target has been deemed to be an Exclusive Target in accordance with Article 4. 

  
 16 

 (v) Regulatory Activities. Subject to the Retained Rights, except as otherwise set
forth in this Section 3.1(v), as between the Parties, Licensee shall have the sole right to prepare, obtain and maintain Drug Approval Applications (including the setting of the overall regulatory strategy therefor), other Regulatory Approvals
and other submissions (including INDs) and to conduct communications with the Regulatory Authorities, for Products in the Field in the Territory in the name of Licensee (or its Affiliate or Sublicensee, as applicable). Upon request by Licensee,
MedImmune will provide Licensee a right of reference to [***] solely in territories where such right of reference may be utilized, and for such time as the [***] is active. 

3.2 Commercialization. 

(i) Responsibility. As between the Parties, Licensee shall be solely responsible for Commercialization of the Licensed Products
in the Field throughout the Territory at Licensee’s own cost and expense. Without limitation of Section 3.2(ii), Licensee shall use Commercially Reasonable Efforts to Commercialize Products in the Major Markets. 

(ii) Commercialization Records. Without limitation of Section 5.8, Licensee shall maintain complete and accurate books and records
pertaining to Commercialization of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under this Agreement and which shall be in compliance with Applicable Law and properly reflect all work done and results
achieved in the performance of its Commercialization activities. Such records shall be retained by Licensee for [***] or for such longer period as may be required by Applicable Law. 

3.3 Compliance with Applicable Law. Licensee shall and shall cause its Affiliates to, comply with all Applicable Law with respect
to the Exploitation of Licensed Products. 
 3.4 Technology Transfer. 

(i) Promptly following the payment of the Upfront Fee set forth in Section 5.1, MedImmune shall deliver or have delivered the
MedImmune Know-How as set forth in Schedule 8. 
 (ii) Such delivery
of MedImmune Know-How will include the delivery of [***]. Licensee is [***]. 
 (iii)
MedImmune shall allocate sufficient personnel, familiar with such MedImmune Know-How, to efficiently conduct and complete such transfer to Licensee (or its designee) as promptly as is reasonably
practicable, and shall make its personnel reasonably available for [***] to answer questions reasonably posed by Licensee (or its designee) to enable the use of the MedImmune Know-How and respond to any
inquiries of any Regulatory Authority relating to the MedImmune Know-How. 
 (iv) If Licensee
[***] the Development or Commercialization of Licensed Compounds and Licensed Products, MedImmune shall [***]. If MedImmune [***]. 
 3.5
Manufacturing of Licensed Products. As between the Parties, Licensee shall have the sole responsibility for, at its expense, Manufacturing (or having Manufactured) and supplying the Licensed Compounds and Products for its Development and
Commercialization activities in the Territory. 

  
 17 

 ARTICLE 4 

NOMINATION OF EXCLUSIVE TARGETS FOR HLE TECHNOLOGY 

4.1 Target Nomination Period. Licensee shall have [***] (the “Target Nomination Period”) to nominate two
(2) Targets to be considered for a license in relation to Exploitation of HLE Products under the terms of this Agreement (such a Target, an “Exclusive Target”). 

4.2 Target Nomination Process. Should Licensee wish to nominate a Target during the Target Nomination Period, Licensee shall
notify MedImmune in writing of such Target(s). MedImmune will have [***] to respond to such notification as to whether the Exclusive Target(s) requested is/are available. If such Target is available as an Exclusive Target, then as of the date of
Licensee’s receipt of such notice, such Target shall thereafter be deemed to be an Exclusive Target. If such Target is not available as an Exclusive Target, MedImmune shall state the reason(s) therefor in such notice. For the avoidance of
doubt, MedImmune will have no obligation to share any Confidential Information of its own or any confidential information of any Third Party in connection with any such reasons,. 

4.3 Permitted Refusal. MedImmune may refuse the request for a Target to become an Exclusive Target only in the following
circumstances: (i) MedImmune has initiated good faith discussions with a Third Party for a license to products directed to such Target, provided that MedImmune shall promptly notify Licensee in writing if such discussions terminate and no
license agreement for such Target has been executed with such Third Party; (ii) MedImmune has granted such rights under the HLE Technology to develop products directed to such Target to a Third Party; or (iii) MedImmune and/or its
Affiliates has itself initiated a research project relating to such Target, using all or part of the MedImmune HLE Patents, that it intends in good faith to continue to Develop. 

ARTICLE 5 
 PAYMENTS AND
RECORDS 
 5.1 Upfront Payment. In partial consideration of the rights granted by MedImmune to Licensee hereunder, on the
date of full execution of this Agreement, Licensee shall pay MedImmune a nonrefundable and noncreditable upfront amount equal to ten million Dollars ($10,000,000) (the “Upfront Fee”). 

5.2 Milestones. 
 (i)
Development and Regulatory Milestones for Flu A Products. In partial consideration of the rights granted by MedImmune to Licensee hereunder, Licensee shall pay to MedImmune the following payments within [***] after the achievement by Licensee,
its Affiliates or its Sublicensees of each of the following milestone events for the first Flu A Product to achieve such milestone, which payment shall be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone
event: 
 [***] 

  
 18 

 Each milestone payment in this Section 5.2(i) shall be payable only upon the first achievement of such
milestone and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Flu A Product. For clarity, the maximum total amount payable under this Section 5.2(i), if all milestone events
are achieved, is Ninety Two Million Dollars ($92,000,000). 
 (ii) Skipped Development and Regulatory Milestones for Flu A Products.
If, at any time, with respect to a Flu A Product, the achievement of a milestone described in (A) [***] with respect to which a payment is due hereunder and any of preceding milestones in [***] have not been achieved; or (B) [***] with respect
to which a payment is due hereunder and the preceding milestones in [***] have not been achieved; or (C) [***] has occurred with respect to which a payment is due hereunder and the preceding milestone in [***] has not been achieved; with
respect to such Flu A Product (the latter of (A), (B) and (C), a “Skipped Flu A Milestone”), then each such Skipped Flu A Milestone payment shall become due and payable concurrently with the milestone payment for the achieved
milestone, with respect to which payment is due. 
 (iii) Development and Regulatory Milestones for Flu B Products. In partial
consideration of the rights granted by MedImmune to Licensee hereunder, Licensee shall pay to MedImmune the following payments within [***] after the achievement by Licensee, its Affiliate or its Sublicensee of each of the following milestone events
for the first Flu B Product to achieve such milestone, which payment shall be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone event: 

[***]. 
 Each milestone payment in this Section 5.2(iii)
shall be payable only upon the first achievement of such milestone and no amounts shall be due for subsequent or repeated achievements of such milestone, whether for the same or a different Flu B Product. For clarity, the maximum total amount
payable under this Section 5.2(iii), if all milestone events are achieved, is Fifty One Million Dollars ($51,000,000). 
 (iv)
Skipped Development and Regulatory Milestones for Flu B Products. If, at any time, with respect to a Flu B Product, the achievement of a milestone described in (A) [***] with respect to which a payment is due hereunder and any of preceding
milestones in [***] have not been achieved; or (B) [***] with respect to which a payment is due hereunder and the preceding milestones in [***] have not been achieved; or (C) [***] has occurred with respect to which a payment is due hereunder
and the preceding milestones in [***] have not been achieved with respect to such Flu B Product (the latter of (A), (B) and (C), a “Skipped Flu B Milestone”), then each such Skipped Flu B Milestone payment shall become due and
payable concurrently with the milestone payment for the achieved milestone, with respect to which payment is due. For clarity, the date of achievement of each Skipped Flu B Milestone shall be deemed to be the date that such Skipped Flu B Milestone
becomes due and payable in accordance with this subsection (iv). 
 (v) Development and Regulatory Milestones for Bispecific Products.
Any bispecific product that meets both the definition of Flu A Product and Flu B Product shall be deemed to be both a Flu A Product and a Flu B Product for all purposes under this Agreement, including Section 5.2. 

  
 19 

 (vi) Commercial Milestones. In partial consideration of the rights granted by
MedImmune to Licensee hereunder, Licensee shall pay to MedImmune the following payments, which shall be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone event: 

(a) in the event that the aggregate of all Net Sales of all Licensed Products made by Licensee or any of its Affiliates or its
or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to MedImmune [***]; and 
 (b)
in the event that the aggregate of all Net Sales of all Licensed Products made by Licensee or any of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to
MedImmune [***]; and 
 (c) in the event that the aggregate of all Net Sales of all Licensed Products made by Licensee or any
of its Affiliates or its or their Sublicensees in a given Calendar Year exceeds [***] for such Calendar Year, Licensee shall pay to MedImmune [***]. 
 Each
such milestone payment shall be due within [***] in such Calendar Year (or, if applicable, within [***] in a Calendar Year in which such milestone was achieved). Each milestone payment in this Section 5.2(vi) shall be payable only upon the
first achievement of such milestone in a given Calendar Year and no amounts shall be due for subsequent or repeated achievements of such milestone in subsequent Calendar Years. For clarity, the maximum total amount payable under this
Section 5.2(vi), if all milestone events are achieved, is Two Hundred Million Dollars ($200,000,000). 
 (vii) Development and
Regulatory Milestones for [***] Products: In the event an HLE Product is a [***] Product, Licensee shall pay on a [***] Product by [***] Product basis, the following payments within [***] after the first achievement of each of the following
milestone events by such [***] Product. Such milestones will be nonrefundable, noncreditable and fully earned upon the achievement of the applicable milestone event: 

[***] 
 For clarity, the maximum total amount
payable under this Section 5.2(vii) for each [***] Product, if all milestone events are achieved, is Two Hundred Fifty Thousand Dollars ($250,000). No payments are due under this Section 5.2(vii) for any Flu A Product or Flu B Product.

 (viii) Determination that Milestones Have Occurred. Licensee shall notify MedImmune promptly of the achievement of each of the
events identified as a milestone in Section 5.2(i), (iii), (vi) or (vii). In the event that, notwithstanding the fact that Licensee has not provided MedImmune such a notice, MedImmune believes that any such milestone has been achieved, it shall
so notify Licensee in writing and the Parties shall promptly meet and discuss in good faith whether such milestone has been achieved. Any dispute under this Section 5.2(viii) regarding whether or not such a milestone has been achieved shall be
subject to resolution in accordance with Section 11.6. 

  
 20 

 5.3 Royalties. 

(i) Royalty Rates for Licensed Products. As further consideration for the rights granted to Licensee hereunder, commencing upon the
First Commercial Sale of a Licensed Product in the Territory, Licensee shall pay to MedImmune a royalty on aggregate Net Sales of Licensed Products in the Territory during each Calendar Year at the following rates: 

[***] 
 (ii) Royalty
Rates for HLE Products. As further consideration for the rights granted to Licensee hereunder, commencing upon the First Commercial Sale of an HLE Product in the Territory, Licensee shall pay to MedImmune a royalty on Net Sales of each HLE
Product in the Territory during each Calendar Year at a rate of [***]. The HLE Royalty is not payable for any Licensed Product. 
 (iii)
Royalties due under Humabs Agreement. Licensee shall assume full responsibility for royalties due under the Humabs Agreement occurring as a result of the Development or Commercialization of Licensed Compounds and Licensed Products under this
Agreement and no reduction as set forth in Section 5.3(vi) shall apply to any license obtained or payments made under the Humabs Agreement. 

(iv) Blended Royalty. Licensee acknowledges that [***]. The Parties agree that the royalty rates set forth in Sections 5.3(i) and
5.3(ii) reflect an efficient and reasonable blended allocation of the value provided by MedImmune to Licensee. 
 (v) Royalty Term.
Licensee shall have no obligation to pay any royalty with respect to Net Sales of any Product in any country after the Royalty Term for such Product in such country has expired. Upon expiry of the Royalty Term with respect to a Product in any
country, the license grants to Licensee in Section 2.1, as applicable, with respect to such Product shall convert to an irrevocable, perpetual, royalty-free license and shall become fully paid-up with
respect to such country. 
 (vi) Reductions. In the event that: 

(a) During the Royalty Term for a Product in a country in the Territory, the Exploitation of such Product is not Covered by a Valid
Claim of any MedImmune Patent, MedImmune FluAB Patent, or MedImmune HLE Patent, as applicable, in such country [***], then the applicable royalty rate(s) set forth in Section 5.3(i) or (ii) with respect to such country, each shall be
reduced [***]; 
 (b) Licensee enters into an agreement with a Third Party in order to obtain a license to a Third Party intellectual
property right with respect to a Product that is [***] such Product in the Field in a country in the Territory, Licensee shall be entitled to deduct from royalties payable hereunder in a given Calendar Year with respect to such Product in such
country [***] of amounts paid to such Third Party in such Calendar Year under such agreement, [***]. 

  
 21 

 (vii) Maximum Amount of Royalty Reduction. In no event shall the amounts payable to
MedImmune under this Section 5.3 be reduced [***]. For the avoidance of doubt such royalty reductions payable to MedImmune set forth in Section 5.3(vi) do not apply to any royalties due and payable by MedImmune under the Humabs Agreement.
Licensee shall remain responsible for such royalties as set forth in the Humabs Agreement (whether subject to reduction or not) in accordance with Section 5.3(iii). 

5.4 Royalty Payments and Reports. Licensee shall calculate all amounts payable to MedImmune pursuant to Section 5.3(i)
and/or 5.3(ii) (as applicable) at the end of each Calendar Quarter, which amounts shall be converted to Dollars, in accordance with Section 5.5. Licensee shall pay to MedImmune the royalty amounts due with respect to a given Calendar Quarter
within [***] after the end of such Calendar Quarter, [***]. Each payment of royalties due to MedImmune shall be accompanied by a statement specifying, on a Product-by-
Product basis, the amount of Invoiced Sales, Net Sales and aggregate deductions taken to arrive at Net Sales attributable to each Product in each country the Territory during the applicable Calendar Quarter (including such amounts expressed
in local currency and as converted to Dollars) and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter. Without limiting the generality of the foregoing, Licensee shall require its Affiliates and
Sublicensees to account for their Net Sales and to provide such reports with respect thereto, as if such sales were made by Licensee. 

5.5 Mode of Payment; Offsets. All payments to MedImmune under this Agreement shall be made by deposit of Dollars in the requisite
amount to such bank account as MedImmune may from time to time designate by notice to Licensee. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales
expressed in currencies other than Dollars), Licensee shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s or Sublicensee’s, as applicable, standard conversion methodology consistent
with GAAP. Except as expressly set forth in Section 5.3(vi), Licensee shall have no right to offset, set off or deduct any amounts from or against the amounts due to MedImmune hereunder. 

5.6 Taxes. 
 (i)
General. The upfront payment, milestones and royalties payable by Licensee to MedImmune pursuant to this Agreement (each, a “Payment”) shall be paid free and clear of any and all taxes (which, for clarity, shall be the
responsibility of Licensee), except for any withholding taxes required by Applicable Law. Except as provided in this Section 5.6, MedImmune shall be solely responsible for paying any and all taxes (other than withholding taxes required by
Applicable Law to be deducted from Payments and remitted by Licensee) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Licensee shall deduct or withhold from the Payments any taxes that it is
required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if MedImmune is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it may deliver to Licensee
or the appropriate governmental authority (with the assistance of Licensee to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Licensee
of its obligation to withhold such tax and Licensee shall apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that Licensee has received evidence of MedImmune’s delivery of all applicable forms (and,
if necessary, its receipt of appropriate governmental 

  
 22 

 
authorization) [***] prior to the time that the Payments are due. If, in accordance with the foregoing, Licensee withholds any amount, it shall pay to MedImmune the balance when due, make
timely payment to the proper taxing authority of the withheld amount and send to MedImmune proof of such payment [***] following such payment. In the event of a change in the applicability or rate of withholding tax in relation to a Payment due to
any structural arrangements of Licensee (such as but not limited to location from which Payments are made, or Licensee assigning rights or obligations under the Agreement), Licensee shall bear any additional withholding tax arising. In the
event of a change in the applicability or rate of withholding tax for other reasons, the Parties shall discuss in good faith the extent to which any additional withholding tax may be mitigated and to the extent mitigation cannot be found, share the
additional withholding tax arising. 
 (ii) Indirect Taxes. Notwithstanding anything contained in Section 5.6(i), this
Section 5.6(ii) shall apply with respect to Indirect Taxes. “Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes. All Payments are exclusive of Indirect Tax. If any Indirect
Tax is chargeable in respect of any Payments, Licensee shall pay Indirect Tax at the applicable rate in respect of any such Payments following the receipt of an Indirect Tax invoice in the appropriate form issued by MedImmune in respect of those
Payments, such Indirect Tax to be payable on the later of the due date of the payment of the Payments to which such Indirect Tax relates and [***] after the receipt by Licensee of the applicable invoice relating to that Indirect Tax payment. 

5.7 Interest on Late Payments. If any payment due to either Party under this Agreement is not paid when due, then such paying
Party shall pay interest thereon (before and after any judgment) at [***] on the date said payment is due, such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest. 

5.8 Financial Records. Licensee shall and shall cause its Affiliates and its and their Sublicensees to, keep complete and
accurate financial books and records pertaining to the Commercialization of Licensed Products hereunder, including books and records of Invoiced Sales and Net Sales of Licensed Products, in sufficient detail to calculate and verify all amounts
payable hereunder (such books and records, the “Licensee Records”). Licensee shall and shall cause its Affiliates and its and their Sublicensees to, retain the Licensee Records until the later of (i) [***] after the end of the
period to which the Licensee Records pertain, (ii) the expiration of the applicable tax statute of limitations (or any extensions thereof) and (iii) for such period as may be required by Applicable Law. 

5.9 Audit Rights. 
 (i)
At the request of MedImmune, Licensee shall and shall cause its Affiliates and its and their Sublicensees to, permit an independent certified public accountant designated by MedImmune, and reasonably acceptable by Licensee (the
“Auditor”), at reasonable times and upon reasonable notice, to audit the Licensee Records to ensure the accuracy of all reports and payments made hereunder. 

  
 23 

 (ii) At Licensee’s request, the Auditor shall enter into a confidentiality
agreement with Licensee on reasonable and customary terms. All Licensee Records are and shall remain the Confidential Information of Licensee. The Auditor shall only use the Licensee Records for the purpose of verifying payments due hereunder, and
shall not disclose the Licensee Records to MedImmune or any Third Party. The Auditor may only share the results of the audit with MedImmune. 

(iii) Any audit shall be limited to the Licensee Records for [***] prior to notification of such audit. MedImmune shall not perform an
audit [***]. 
 (iv) Except as provided below, the cost of this audit shall be borne by MedImmune, unless the audit reveals, with
respect to a period, an underpayment of [***], in which case Licensee shall bear the cost of the audit. Unless disputed pursuant to Section 5.10 below, if such audit concludes that (a) additional amounts were owed by Licensee, Licensee
shall pay the additional amounts, with interest from the date originally due as provided in Section 5.7, or (b) excess payments were made by Licensee, MedImmune shall reimburse such excess payments, in either case ((a) or (b)), within
[***] after the date on which such audit is completed by MedImmune. 
 5.10 Audit Dispute. In the event of a dispute with
respect to any audit under Section 5.9, MedImmune and Licensee shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute [***], the dispute shall be submitted
for resolution to a certified public accounting firm jointly selected by each Party’s certified public accountants or to such other Person as the Parties shall mutually agree (the “Dispute Auditor”). The decision of the
Dispute Auditor shall be final and the costs of such arbitration as well as the initial audit shall be borne between the Parties in such manner as the Dispute Auditor shall determine. [***] after such decision and in accordance with such
decision, Licensee shall pay the additional amounts, with interest from the date originally due as provided in Section 5.7 or MedImmune shall reimburse the excess payments, as applicable. For clarity, the Dispute Auditor shall not be the same
certified public accountant as the Auditor who conducted the audit subject to any such dispute. 
 ARTICLE 6 

INTELLECTUAL PROPERTY 

6.1 Ownership of Intellectual Property. 

(i) Ownership of Technology. Subject to Section 6.1(ii), as between the Parties, each Party shall own and retain all right,
title and interest in and to any and all: (i) Know-How, Improvements and other inventions that are conceived, discovered, developed or otherwise made by or on behalf of such Party or its Affiliates or its
or their (sub)licensees (or Sublicensee(s)), as applicable, under or in connection with this Agreement, whether or not patented or patentable and any and all Patents and other intellectual property rights with respect thereto; and (ii) other Know-How, inventions, Patents and other intellectual property rights that are owned or otherwise controlled (other than pursuant to the license grants set forth in Sections 2.1 or 10.7(i)) by such Party
or its Affiliates or its or their (sub)licensees (or Sublicensees) (as applicable) outside of this Agreement. For clarity, the Parties are not collaborating on the Development of Products under this Agreement and do not expect or intend that any
jointly created intellectual property will arise under this Agreement. 

  
 24 

 (ii) United States Law. The determination of whether
Know-How, Improvements and other intellectual property are conceived, discovered, developed or otherwise made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other
intellectual property rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States as such law exists as of the Effective Date irrespective of where or when such conception, discovery,
development or making occurs. 
 6.2 Maintenance and Prosecution of Patents. 

(i) MedImmune Patents. 

(a) As between the Parties, and for so long as [***] is the Prosecuting Party, as defined below, [***] shall have the first right, but
not the obligation, through counsel of its choice, to prepare, file, prosecute and maintain the MedImmune Patents, including any related interference, re-issuance,
re-examination and opposition proceedings with respect thereto, in the Territory, and in each case, [***]. Notwithstanding the foregoing, [***]. 

(b) For purposes of this Section 6.2(i), [***] shall be the “Prosecuting Party” unless [***] assumes its right to
step in as set forth below in Section 6.2(i)(c) and 6.2(ii), in which event [***] shall be the Prosecuting Party with respect to the applicable MedImmune Patent(s). The Prosecuting Party shall periodically inform the other Party of all material
steps with regard to the preparation, filing, prosecution and maintenance of the MedImmune Patents in the Territory, including by providing the non-Prosecuting Party with (i) a copy of material
communications to and from any patent authority in the Territory regarding such Patents; and (ii) drafts of any material filings or responses to be made to such patent authorities sufficiently in advance of submitting such filings or responses
so as to allow for a reasonable opportunity for the review and comment thereupon. The Prosecuting Party shall consider in good faith, and if requested discuss with the non-Prosecuting Party, the requests and
suggestions of the non-Prosecuting Party with respect to such drafts. 
 (c) If, as between
the Parties, [***] (1) decides not to prepare, file, prosecute or maintain a MedImmune Patent in a country in the Territory, [***] as otherwise agreed to by the Parties in writing, then subject to any rights of any Third Parties under any In-License Agreement, [***] shall have the right, in its sole discretion and exercisable by written notice to [***], but not the obligation, to assume the control and direction of the preparation, filing,
prosecution and maintenance of such MedImmune Patents at its sole cost and expense in such country, whereupon [***] shall be deemed the Prosecuting Party with respect to such Patent. [***] shall provide prior written notice to [***] in the events
set forth in subclause (1) reasonably in advance of any upcoming deadlines or extension thereof relating to such MedImmune Patent(s) and shall reasonably cooperate in the transfer of the applicable patent files to [***] or its counsel promptly
following its receipt of [***] election to become the Prosecuting Party with respect to such MedImmune Patent(s). For the avoidance of doubt, (A) [***] rights under this Section 6.2 will [***], and (B) in the case of subclause
(2) above, [***] rights will [***] in the case where [***, and to those MedImmune Patents containing claims that Cover a Flu B Compound or a Flu B Product in the case where [***]. 

  
 25 

 (ii) Continuing Patent Applications. [***] shall notify [***] within [***]
following [***] receipt of a Notice of Allowance for any MedImmune Patent that Covers a Licensed Compound or a Licensed Product. At [***] request, [***] will discuss in good faith with [***] the filing of one or more additional Patents containing
only claims Covering a Licensed Compound or a Licensed Product and that are eligible to claim benefit from such MedImmune Patent. In the event [***] does not wish to file any such additional Patents, [***] shall have the right, in its sole
discretion and exercisable by written notice to [***], but not the obligation, to file any such additional Patents as the Prosecuting Party at its sole cost and expense; provided, however, [***] shall have the right to review and approve the
claims for such additional Patents prior to filing the same to ensure such Patents contain only claims Covering a Licensed Compound or a Licensed Product. [***] shall not amend such claims to contain, or file any additional Patents claiming priority
to any MedImmune Patent and containing, any claims that do not Cover a Licensed Compound or a Licensed Product. For any such additional Patents claiming priority to any MedImmune Patent [***] intends to file, [***] shall have the right to review and
approve the claims prior to filing the same to ensure such Patents contain only claims Covering a Licensed Compound or a Licensed Product. [***] approval pursuant to this Section 6.2(ii) shall not be unreasonably withheld. 

(iii) MedImmune FluAB Patents and MedImmune HLE Patents. [***] has the sole right to prepare, file, prosecute and maintain the MedImmune
FluAB Patents and the MedImmune HLE Patents, including any related interference, re-issuance, re-examination and opposition proceedings with respect thereto, at [***]
sole cost and expense. 
 (iv) Cooperation. The non-Prosecuting Party shall, and shall cause
its Affiliates to, assist and cooperate with the Prosecuting Party, as the Prosecuting Party may reasonably request from time to time, in the preparation, filing, prosecution and maintenance of the MedImmune Patents, MedImmune FluAB Patents, and the
MedImmune HLE Patents, in the Territory under this Agreement, including that the non-Prosecuting Party shall, and shall ensure that its Affiliates, provide access to relevant documents and other evidence and
make its employees available at reasonable business hours; provided, however, that neither Party shall be required to provide legally privileged information with respect to such intellectual property unless and until procedures reasonably
acceptable to such Party are in place to protect such privilege; and provided, further, that the Prosecuting Party shall reimburse the non-Prosecuting Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

6.3 Patent Term Extension and Supplementary Protection Certificate. As between the Parties, [***] shall have the first right to
make decisions regarding, and to apply for, patent term extensions for the MedImmune Patents in the Territory, including the United States with respect to extensions pursuant to 35 U.S.C. §156 et. seq. and in other jurisdictions pursuant
to supplementary protection certificates, and in all jurisdictions with respect to any other extensions that are now or become available in the future, wherever applicable; provided that [***] prior written notice before filing for any such
patent term extension, and consult reasonably and in good faith with [***] to determine the course of action with respect to such filings. Notwithstanding the foregoing, if [***] shall have the right to make decisions regarding, and to apply for,
patent term extensions for the MedImmune Patents [***]. [***], including by taking such action as patent holder as is required under any Applicable Law to obtain such extension or supplementary protection certificate. 

  
 26 

 6.4 Enforcement of Patents. 

(i) Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened infringement of the MedImmune
Patents that Cover a Licensed Compound or a Licensed Product in any jurisdiction in the Territory (an “Infringement”). 

(ii) Enforcement of MedImmune Patents. 

(a) As between the Parties, [***] shall have the first right, but not the obligation, to prosecute any Infringement with respect to
MedImmune Patents containing claims Covering a Licensed Compound or a Licensed Product (“Product Infringement”), including as a defense or counterclaim in connection with any Infringement claim by any Third Party, at [***] sole cost
and expense, using counsel of [***] choice. [***] shall have the sole right, but not the obligation, to prosecute any other Infringement in connection with any other MedImmune Patents. 

(b) For purposes of this Section 6.4 and subject to the remainder of this subsection (b), [***] shall be the “Enforcing
Party”. In the event [***] prosecutes any such Infringement in the Field in the Territory, [***] shall have the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost and expense;
provided that [***] shall retain control of the prosecution of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith, subject to the remainder of this
Section 6.4. If [***] it or its designee does not take commercially reasonable steps to prosecute a Product Infringement in the Field against a Third Party (x) within [***] following the first notice provided above with respect to such
Infringement or (y) provided such date occurs after the first such notice of such Infringement is provided, [***] before the time limit or extensions thereof, if any, set forth in appropriate laws and regulations for filing of such
actions, whichever comes first, then [***] may prosecute such Infringement in the Field at its sole cost and expense, using counsel of [***] choice, whereupon the [***] shall be deemed the Enforcing Party with respect to such Infringement. In the
event [***] prosecutes any such Infringement in the Field in the Territory, pursuant to this Section 6.4(b), [***] shall have the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its sole cost
and expense; provided that [***] shall retain control of the prosecution of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith. For clarity, in the case of
subclause (1) above, [***]. 
 (c) Any amounts recovered or obtained by the Enforcing Party in connection with a Product
Infringement (whether as damages, royalties, license fees, or otherwise in judgment or settlement derived therefrom)(“Damages”), shall first be used to reimburse each Party pro rata for its costs and expenses (including reasonable
attorney fees) incurred in connection with such Infringement. Any such Damages recovered or obtained to the extent attributable to a Licensed Compound or a Licensed Product and in excess of such costs and expenses shall be [***]. If the Damages
received are for other products in addition to Licensed Compounds and Licensed Products and the portion of such Damages attributable solely to Licensed Compounds and 

  
 27 

 
Licensed Products cannot be clearly ascertained from the award, then the Parties shall promptly seek to agree in good faith on a reasonable allocation between the Licensed Compound and Licensed
Products and such other products to which such Damages apply. If the Parties are unable to agree on such an allocation with [***] of undertaking to do so, then either Party may initiate dispute resolution proceedings in accordance with
Section 11.6. Except as set forth above, any amounts recovered or obtained by an Enforcing Party shall be retained by such Party. 

(iii) Enforcement of MedImmune FluAB Patents and MedImmune HLE Patents. As between the Parties, [***] shall have the sole right, but not
the obligation, to prosecute any Infringement with respect to the MedImmune FluAB Patents and the MedImmune HLE Patents. 
 (iv)
Cooperation. 
 (a) The Parties agree to cooperate fully in any Infringement action pursuant to this Section 6.4, including
by making the inventors, applicable records and documents (including laboratory notebooks) with respect to the relevant Patents available to the Enforcing Party on the Enforcing Party’s request. The Enforcing Party shall keep the other Party
promptly informed of all material steps and developments in any action or proceeding described in this Section 6.4. Such other Party shall have the right to consult with the Enforcing Party regarding such enforcement of the MedImmune Patents
and to review any material filings or correspondence prior to submission, and to comment thereon to the Enforcing Party or its designated outside counsel; provided, however, the Controlling Party shall not be prohibited from taking any
necessary action in connection with any activity contemplated under this Section 6.4 except as set forth in subsection (c) below. The Enforcing Party shall reasonably consider in good faith and discuss with such other Party the comments
offered by such other Party. The Enforcing Party shall promptly provide such other Party with copies of all material documents filed or received in connection with such Infringement action. 

(b) With respect to an action controlled by the applicable Enforcing Party, the other Party shall, and shall cause its Affiliates to,
assist and cooperate with the Enforcing Party, as the Enforcing Party may reasonably request from time to time, in connection with its activities set forth in this Section 6.4, including where necessary, furnishing a power of attorney solely
for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees available at reasonable business hours; provided that the Enforcing
Party shall reimburse such other Party for its reasonable and verifiable costs and expenses incurred in connection therewith. 
 (c)
Unless otherwise set forth herein, the Enforcing Party shall have the right to settle such claim; provided that neither Party shall have the right to make any admission in connection with any Infringement litigation or settle any
Infringement litigation under this Section 6.4 in a manner that has or would reasonably be expected to have a material adverse effect on the rights or interest of the other Party hereunder or in a manner that imposes any costs or liability on
or involves any admission by, the other Party, without the express written consent of such other Party (which consent shall not be unreasonably withheld, conditioned or delayed). 

  
 28 

 6.5 Invalidity or Unenforceability Defenses or Actions. 

(i) Notice. Each Party shall promptly notify the other Party in writing of any alleged or threatened assertion of invalidity or
unenforceability of any of the MedImmune Patents that Cover a Licensed Compound or a Licensed Product in any jurisdiction in the Territory by a Third Party and of which such Party becomes aware, including any certification filed under the BPCI Act
claiming that any MedImmune Patents are invalid or unenforceable or claiming that any MedImmune Patents would not be infringed by the making, having made, use, offer for sale, sale or import of a product for which an application under the BPCI Act
is filed or any equivalent or similar certification or notice in any other jurisdiction in the Territory (an “Invalidity Action”). 

(ii) Control of Defense. [***] shall have the first right, but not the obligation, to defend and control the defense of an Invalidity
Action at [***] sole cost and expense, using counsel of MedImmune’s choice. If [***] it or its designee elects not to defend or control such Invalidity Action in the Territory or otherwise fails to initiate and maintain the defense of any such
claim, suit or proceeding, then subject to any rights of Third Parties under any In-License Agreements, [***] may defend and control such Invalidity Action at [***] sole cost and expense, using counsel of
[***] choice. For clarity, in the case of [***]. 
 (iii) Cooperation. 

(a) The Party controlling the defense of an Invalidity Action with respect to a Patent pursuant to Section 6.5(ii) shall be the
“Controlling Party.” The other Party in such an action shall, and shall cause its Affiliates to, assist and cooperate with the Controlling Party, as such Controlling Party may reasonably request from time to time in connection with
its activities set forth in this Section 6.5, including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and other
evidence and making its employees available at reasonable business hours; provided that the Controlling Party shall reimburse the non-Controlling Party for its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. 

(b) In connection with any activities with respect to a defense, claim or counterclaim relating to the MedImmune Patents pursuant to
this Section 6.5, the Controlling Party shall keep the other Party promptly informed of all material steps and developments in any action or proceeding described in this Section 6.5. Such other Party shall have the right to consult with
the Controlling Party regarding such defense of such Invalidity Action and to review any material filings or correspondence prior to submission, and to comment thereon to the Controlling Party or its designated outside counsel; provided,
however, the Controlling Party shall not be prohibited from taking any necessary action in connection with any activity contemplated under this Section 6.5, except as set forth in subsection (c) below. The Controlling Party shall
reasonably consider in good faith and discuss with such other Party the comments offered by such other Party. The Controlling Party shall promptly provide such other Party with copies of all material documents filed or received in connection with
such Invalidity Action. 

  
 29 

 (c) Unless otherwise set forth herein, the Controlling Party shall have the right to
settle such claim; provided that neither Party shall have the right to make any admission in connection with any Invalidity Action or settle any Invalidity Action under this Section 6.5 in a manner that has or would reasonably be
expected to have a material adverse effect on the rights or interest of the other Party hereunder or in a manner that imposes any costs or liability on or involves any admission by, the other Party, without the express written consent of such other
Party (which consent shall not be unreasonably withheld, conditioned or delayed). 
 6.6 Privileged Information. Neither Party
shall be required to provide legally privileged information relating to any Infringement contemplated under this Article 6 until procedures and documentation reasonably acceptable to such Party are in place to protect such privilege. 

ARTICLE 7 

CONFIDENTIALITY AND NON-DISCLOSURE 

7.1 Confidentiality Obligations. At all times during the Term and for a period of [***], each Party that receives Confidential
Information (the “Receiving Party”) shall and shall cause its and its Affiliates’ officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or
indirectly, for any purpose, such Confidential Information of the Party that disclosed such Confidential Information (the “Disclosing Party”), except to the extent such disclosure or use is expressly permitted by the terms of this
Agreement. “Confidential Information” means any technical, business or other information of the Disclosing Party that is disclosed or otherwise made available to the other Party in connection with this Agreement or was
disclosed pursuant to the Prior CDA, including any Know-How (including the [***]) or other information relating to the terms of this Agreement (subject to Section 7.2(iii), Section 7.4 and
Section 8.6(v)), information relating to the Licensed Compound or any Licensed Product (including the Regulatory Documentation), any of the MedImmune Intellectual Property, any Know-How or the scientific,
regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 7.1 with respect to any Confidential
Information of the Disclosing Party shall not include any information that the Receiving Party can demonstrate by documentation or other competent evidence: 

(i) is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like through no breach of
this Agreement by the Receiving Party; 
 (ii) was in the Receiving Party’s possession prior to disclosure by the Disclosing
Party without any obligation of confidentiality with respect to such information; 
 (iii) is subsequently received by the Receiving
Party from a Third Party who is not bound by any obligation of confidentiality with respect to such information; 
 (iv) has been
published by a Third Party or otherwise enters the public domain through no fault of the Receiving Party in breach of this Agreement; or 

(v) was independently developed by or for the Receiving Party without reference to the Disclosing Party’s Confidential Information.

  
 30 

 Specific aspects or details of Confidential Information shall not be deemed to be within the public domain
or in the possession of the Receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the Receiving Party. Further, any combination of Confidential Information
shall not be considered in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination
and its principles are in the public domain or in the possession of the Receiving Party. 
 7.2 Permitted Disclosures. Each
Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such disclosure is: 
 (i) made in
response to a valid order of a court of competent jurisdiction or other supra-national, federal, national, regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the reasonable opinion of the
Receiving Party’s legal counsel, such disclosure is otherwise required by law, including by reason of filing with securities regulators; provided, however, that the Receiving Party shall first have given notice to the Disclosing
Party and given the Disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject of such order be held in
confidence by such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided, further, that the Confidential Information disclosed in response to such court or governmental order shall
be limited to that information which is legally required to be disclosed in response to such court or governmental order; 
 (ii) made
by or on behalf of the Receiving Party to the Regulatory Authorities as required in connection with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken to assure
confidential treatment of such information to the extent practicable and consistent with Applicable Law; 
 (iii) made by or on behalf
of the Receiving Party to potential or actual investors, acquirers, merger partners, sublicensees, investment bankers or other financial partners as may be necessary in connection with their evaluation of such potential or actual transaction;
provided, however, that such persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of
confidentiality and non-use of the receiving Party pursuant to this Article 7 [***]. If the Receiving Party is [***], and that any representatives who receive such information will be informed of the
sensitive and proprietary nature of the information and the need to maintain its secrecy and avoid inappropriate usage. 
 7.3 Use of
Name. Except as expressly provided herein, neither Party shall use the name, logo or Trademark of the other Party or any of its Affiliates or any of its or their (sub)licensees (or Sublicensees) (or any abbreviation or adaptation thereof)
in any publication, press release, marketing and promotional material or other form of publicity without the prior written approval of such other Party in each instance. The restrictions imposed by this Section 7.3 shall not prohibit
(i) either Party from making any disclosure identifying the other Party to the extent required or reasonably necessary in connection with its exercise of its rights or obligations under this Agreement and (ii) either Party from making any
disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). 

  
 31 

 7.4 Public Announcements. Neither Party shall issue any public announcement,
press release or other public disclosure regarding this Agreement or its subject matter without the other Party’s prior written consent, except for any such disclosure that is, in the opinion of the disclosing Party’s counsel, required by
Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). In the event a Party is, in the opinion of its counsel, required by Applicable
Law or the rules of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as
far in advance as reasonably practicable (and in no event [***] prior to the anticipated date of disclosure, unless otherwise required by exigent circumstances) so as to provide a reasonable opportunity to comment thereon. Neither Party shall be
required to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the other Party, in accordance with this
Section 7.4; provided that such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable. 

7.5 Publications. The Parties recognize the desirability of publishing and publicly disclosing the results of and information
regarding, activities under this Agreement. Accordingly, Licensee shall be free to publicly disclose the results of and information regarding, activities under this Agreement, subject to prior review for issues of patentability and protection of
such Confidential Information, in a manner consistent with Applicable Law and industry practices, as provided in this Section 7.5. Accordingly, prior to Licensee publishing or publicly disclosing any Confidential Information of MedImmune,
Licensee shall provide the other Party with drafts of proposed abstracts, manuscripts or summaries of presentations that cover such Confidential Information. MedImmune shall respond promptly through its designated representative and in any
event [***] after receipt of such proposed publication or presentation or such shorter period as may be required by the publication or presentation. The Publishing Party agrees to allow a reasonable period [***] to permit filings for patent
protection and to otherwise address issues relating to such Confidential Information or related competitive harm to the reasonable satisfaction of such other Party. In addition, the Publishing Party shall give due regard to comments furnished by
such other Party and such comments shall not be unreasonably rejected.  
 7.6 Return of Confidential Information. Upon
the effective date of the expiration or termination of this Agreement for any reason, either Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information to
which such non-requesting Party does not retain rights under the surviving provisions of this Agreement, at the non-requesting Party’s election, (i) promptly
destroy all copies of such Confidential Information in the possession or control of the non-requesting Party and confirm such destruction in writing to the requesting Party or (ii) promptly deliver to the
requesting Party, at the non-requesting Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the
non-requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted to retain such Confidential Information (x) for purposes of
performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such 

  
 32 

 
Confidential Information for archival purposes and (y) any computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such
non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject
to the terms of this Agreement for the period set forth in Section 7.1. 
 7.7 Privileged Communications. In furtherance of this
Agreement, it is expected that the Parties may, from time to time, disclose to one another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are
made with the understanding that they shall remain confidential in accordance with this Article 7, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection
with the shared community of legal interests existing between MedImmune and Licensee, including the community of legal interests in avoiding infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the
MedImmune Patents. In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the subject matter hereof, the Parties shall, upon either Party’s request, enter into a reasonable and customary joint
defense agreement. In any event, each Party shall consult in a timely manner with the other Party before engaging in any conduct (e.g., producing information or documents) in connection with litigation or other proceedings that could conceivably
implicate privileges maintained by the other Party. Notwithstanding anything contained in this Section 7.7, nothing in this Agreement shall prejudice a Party’s ability to take discovery of the other Party in disputes between them relating
to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery solely by this Section 7.7. 

ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Mutual Representations and Warranties. MedImmune and Licensee each represents and warrants to the other, as of the Effective
Date and, with respect to subsection (d) below, covenants, that: 
 (i) It is a corporation duly organized, validly existing and
in good standing under the laws of the jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

(ii) The execution and delivery of this Agreement and the performance by it of the transactions contemplated hereby have been duly
authorized by all necessary corporate action and do not violate: (a) such Party’s charter documents, bylaws or other organizational documents; (b) in any material respect, any agreement, instrument or contractual obligation to which
such Party is bound; (c) any requirement of any Applicable Law; or (d) any order, writ, judgment, injunction, decree, determination or award of any court or governmental agency presently in effect applicable to such Party; 

  
 33 

 (iii) This Agreement is a legal, valid and binding obligation of such Party
enforceable against it in accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of
specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity); 
 (iv) It
is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations
hereunder; and 
 (v) Neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of its
Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It
will inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or legal or
administrative proceeding is pending or, to the best of its or its Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of it or any such Person performing services hereunder. 

8.2 Additional Representations and Warranties of MedImmune. MedImmune further represents and warrants to Licensee, as of the
Effective Date, that: 
 (i) Schedules 7(A) and 7(B) identify all of the Patents Controlled by MedImmune or its Affiliates as
of the Effective Date that Cover the [***]; 
 (ii) MedImmune Controls the MedImmune Intellectual Property as of the Effective Date
and has the right to grant the licenses and sublicenses specified herein; 
 (iii) MedImmune has not received, and no member of
the AstraZeneca Patent Group has knowledge of, any written notice alleging that (a) any of the MedImmune Patents or the FluAB Patents is invalid or unenforceable or (b) the Development of the Licensed Compound as contemplated herein
infringes any Patent owned by any Third Party; 
 (iv) MedImmune has not received, and no member of the AstraZeneca Patent Group has
knowledge of, any written notice of any claim or threatened claim by any Third Party (a) asserting the misuse or non-infringement of any of the MedImmune Patents or the FluAB Patents, or
(b) challenging MedImmune’s Control of any of the MedImmune Patents or the FluAB Patents; 
 (v) MedImmune has not received
written notice that any MedImmune Patents or FluAB Patents is the subject of any interference, opposition, cancellation or other protest proceeding, or neither MedImmune nor any member of the AstraZeneca Patent Group has any knowledge of any
threatened interference opposition, cancellation or other protest proceeding against any MedImmune Patents or FluAB Patents; 
 (vi)
There are no judgments or settlements against or owed by MedImmune or to MedImmune’s or any member of the AstraZeneca Patent Group’s knowledge, pending litigation against MedImmune or any of its Affiliates or litigation threatened
against MedImmune or any of its Affiliates in writing, in each case relating to [***]; 

  
 34 

 (vii) To the knowledge of MedImmune and each member of the AstraZeneca Patent Group,
there is no actual infringement of any MedImmune Patents or the FluAB Patents by any Third Party; 
 (viii) MedImmune has the right to
use and disclose and to enable Licensee and its Affiliates and Sublicensees to use and disclose (in each case under conditions of confidentiality consistent with Article 7) the MedImmune Know-How to Licensee
as set forth in this Agreement; 
 (ix) All individuals who are current or former officers, employees, agents, advisors, consultants,
contractors or other representatives of MedImmune or any of its Affiliates who are inventors of or have otherwise contributed in a material manner to the creation or development of any MedImmune Intellectual Property have executed and delivered to
MedImmune or the applicable Affiliate a valid and enforceable assignment or other agreement regarding the protection of proprietary information and, where applicable, the assignment (or exclusive license) to MedImmune or such Affiliate of such
Person’s entire right, title and interest in and to any MedImmune Intellectual Property; 
 (x) To MedImmune’s knowledge, no
current officer, employee, agent, advisor, consultant or other representative of MedImmune or any of its Affiliates is in violation of any term of any assignment, license, consulting, employment or other agreement with MedImmune or such Affiliate
regarding the protection of any of the MedImmune Intellectual Property; 
 (xi) Schedule 5 identifies all agreements existing
as of the Effective Date between MedImmune or any of its Affiliates and a Third Party pursuant to which any of the MedImmune Intellectual Property are, or may be, licensed to MedImmune or any of its Affiliates; each such agreement is in effect and
is valid and binding on MedImmune or its Affiliate, enforceable in accordance with its terms, and MedImmune, nor to the knowledge of MedImmune, any other party thereto, is in material breach of, or material default under, any such agreement, and no
event has occurred that, with the giving of notice or lapse of time or both, would constitute a material breach or material default by MedImmune or any of its Affiliates thereunder; and neither MedImmune nor any of its Affiliates has agreed to incur
any other royalty or other payment obligation to any Third Party with respect to the practice, or the grant of rights to Licensee to practice, any of the MedImmune Intellectual Property existing as of the Effective Date with respect to the Licensed
Compound or a Licensed Product under this Agreement, except pursuant to the agreements set forth in Schedule 5; and 
 (xii)
MedImmune has provided to Licensee a true, complete but redacted copy of the [***], including all amendments thereto existing as of the Effective Date. 

8.3 Additional Representations and Warranties of Licensee. Licensee further represents and warrants to MedImmune, as of the
Effective Date, that Licensee: (i) has conducted its own investigation and analysis of (a) the Patent and other proprietary rights of Third Parties as such rights relate to the Exploitation of the Licensed Compound and Licensed Products as
contemplated hereunder and (b) the potential infringement thereof; (ii) understands the complexity 

  
 35 

 
and uncertainties associated with possible claims of infringement of Patent or other proprietary rights of Third Parties, particularly those relating to biopharmaceutical products;
(iii) acknowledges and agrees that it is solely responsible for the risks of such claims except to the extent arising from a breach of MedImmune’s representations and warranties set forth in this Article 8. 

8.4 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR
GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 

8.5 ADDITIONAL WAIVER. LICENSEE AGREES THAT: (i) EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 8.1 AND 8.2, THE MEDIMMUNE
PATENTS ARE LICENSED “AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS”; AND (ii) LICENSEE IS SOLELY RESPONSIBLE FOR DETERMINING WHETHER THE MEDIMMUNE PATENTS HAVE APPLICABILITY OR UTILITY IN LICENSEE’S
CONTEMPLATED EXPLOITATION OF THE LICENSED PRODUCTS AND LICENSEE ASSUMES ALL RISK AND LIABILITY IN CONNECTION WITH SUCH DETERMINATION EXCEPT TO THE EXTENT ARISING FROM A BREACH OF MEDIMMUNE’S REPRESENTATIONS AND WARRANTIES SET FORTH ABOVE. 

8.6 Anti-Bribery and Anti-Corruption Compliance. 

Licensee agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants and
subcontractors hired in connection with the subject matter of this Agreement (together with Licensee, the “Licensee Representatives”) that in connection with the performance of its obligations hereunder: 

(i) The Licensee Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything
else of value in violation of the Anti-Corruption Laws. 
 (ii) The Licensee Representatives shall comply with the Anti-Corruption
Laws and shall not take any action that will, or would reasonably be expected to, cause MedImmune or its Affiliates to be in violation of any such laws or policies. 

(iii) Licensee shall promptly provide MedImmune with written notice of the following events: (i) upon becoming aware of any breach
or violation by Licensee or other Licensee Representative of any representation, warranty or undertaking set forth in Sections 8.6(i) or 8.6(ii) above; or (ii) upon receiving a formal notification that it is the target of a formal investigation
by a governmental authority for a Material Anti-Corruption Law violation or upon receipt of information from any of the Licensee Representatives connected with this Agreement that any of them is the target of a formal investigation by a governmental
authority for a Material Anti-Corruption Law violation, in each case, in connection with this Agreement. 

  
 36 

 (iv) Licensee shall be responsible for any breach of any representation, warranty or
undertaking in this Section 8.6 or of the Anti-Corruption Laws by any Licensee Representative. 
 (v) MedImmune may disclose the
terms of this Agreement or any action taken under this Section 8.6 to prevent a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of Licensee or a Licensee Representative and the payment
terms, to any governmental authority if MedImmune determines, upon advice of counsel, that such disclosure is necessary, provided that MedImmune gives Licensee prompt written notice thereof to the extent permitted by Applicable Laws. 

ARTICLE 9 
 INDEMNITY

 9.1 Indemnification of MedImmune. Subject to Section 9.3, Licensee shall indemnify MedImmune, its
Affiliates and its and their respective directors, officers, employees and agents and defend and save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable attorneys’ fees and
expenses) (collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Third Party Claims”) arising from or occurring as a result of: (i) the
breach by Licensee of this Agreement; (ii) the gross negligence or willful misconduct on the part of Licensee or its Affiliates or its or their Sublicensees or its or their distributors or contractors or its or their respective directors,
officers, employees or agents in performing its or their obligations under this Agreement; or (iii) the Exploitation by Licensee or any of its Affiliates or its or their Sublicensees or its or their distributors or contractors of any Product or
Licensed Compound in or for the Territory, except, in each case ((i), (ii) and (iii)), for those Losses for which MedImmune has an obligation to indemnify Licensee pursuant to Section 9.2 hereof, as to which Losses each Party shall indemnify
the other to the extent of their respective liability. 
 9.2 Indemnification of Licensee. Subject to Section 9.3,
MedImmune shall indemnify Licensee, its Affiliates and its and their respective directors, officers, employees and agents and defend and save each of them harmless, from and against any and all Losses in connection with any and all Third Party
Claims arising from or occurring as a result of: (i) the breach by MedImmune of this Agreement; (ii) the gross negligence or willful misconduct on the part of MedImmune or its Affiliates or its or their respective directors, officers,
employees or agents in performing its obligations under this Agreement; and (iii) the Exploitation by MedImmune or any of its Affiliates or its or their sublicensees or its or their distributors or contractors of any Licensed Product pursuant
to Section 10.7, except, in each case ((i), (ii) and (iii)), for those Losses for which Licensee has an obligation to indemnify MedImmune pursuant to Section 9.1 hereof, as to which Losses each Party shall indemnify the other to the extent
of their respective liability for the Losses. 

  
 37 

 9.3 Indemnification Procedures. 

(i) Notice of Claim. All indemnification claims in respect of a Party, its Affiliates or its or their (sub)licensees or their respective
directors, officers, employees and agents shall be made solely by such Party to this Agreement (the “Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an
“Indemnification Claim Notice”) of any Losses or discovery of fact upon which such indemnified Party intends to base a request for indemnification under this Article 9, but in no event shall the indemnifying Party be
liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is
known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses and Third Party Claims. 

(ii) Control of Defense. The indemnifying Party shall have the right to assume the defense of any Third Party Claim by giving written
notice to the Indemnified Party within [***] after the indemnifying Party’s receipt of an Indemnification Claim Notice. The assumption of the defense of a Third Party Claim by the indemnifying Party shall not be construed as an acknowledgment
that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified Party’s claim for
indemnification. Upon assuming the defense of a Third Party Claim, the indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying Party; provided that it obtains the
prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall immediately
deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third Party Claim and it
is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all
reasonable and documented costs and expenses (including attorneys’ fees and costs of suit) and any Losses incurred by the indemnifying Party in accordance with this Article 9 in its defense of the Third Party Claim. 

(iii) Right to Participate in Defense. Any Indemnified Party shall be entitled to participate in the defense of such Third Party Claim
and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified Party’s sole cost and expense unless (i) the employment thereof has been specifically authorized in
writing by the indemnifying Party in writing (in which case, the defense shall be controlled as provided in Section 9.3(ii)), (ii) the indemnifying Party has failed to assume the defense and employ counsel in accordance with
Section 9.3(ii) (in which case the Indemnified Party shall control the defense) or (iii) the interests of the Indemnified Party and the indemnifying Party with respect to such Third Party Claim are sufficiently adverse to prohibit the
representation by the same counsel of both Parties under Applicable Law, ethical rules or equitable principles (in which case, the Indemnified Party shall control its defense). 

  
 38 

 (iv) Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that shall not result in the Indemnified Party becoming subject to injunctive or other relief or otherwise adversely affecting the business of the Indemnified Party in any manner and as to which the
indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise
dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the Third
Party Claim in accordance with Section 9.3(ii), the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided it obtains the prior written
consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend
against such Third Party Claim; provided that the Indemnified Party shall not settle any Third Party Claim without the prior written consent of the indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).

 (v) Cooperation. Regardless of whether the indemnifying Party chooses to defend or prosecute any Third Party Claim, the Indemnified
Party shall and shall cause each indemnitee to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials
and appeals as may be reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to the indemnifying Party to and reasonable retention by the Indemnified Party of, records and
information that are reasonably relevant to such Third Party Claim and making Indemnified Parties and other employees and agents available on a mutually convenient basis to provide additional information and explanation of any material provided
hereunder and the indemnifying Party shall reimburse the Indemnified Party for all its, its Affiliates’ and its and their (sub)licensees’ or their respective directors’, officers’, employees’ and agents’, as applicable,
reasonable and verifiable out-of-pocket expenses in connection therewith. 

(vi) Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the
Indemnified Party and its Affiliates and its and their respective directors, officers, employees and agents, as applicable, in connection with any claim shall be reimbursed on a Calendar Quarter, without prejudice to the indemnifying Party’s
right to contest the Indemnified Party’s right to indemnification and subject to refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

9.4 Special, Indirect and Other Losses. EXCEPT (i) IN THE EVENT THE WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR OF A
PARTY’S BREACH OF ITS OBLIGATIONS UNDER [***] and/or ARTICLE 7, OR (ii) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 9, NEITHER
PARTY NOR ANY OF ITS AFFILIATES OR (SUB)LICENSEES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL OR PUNITIVE DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY. 

  
 39 

 9.5 Insurance. Licensee shall have and maintain such types and amounts
of insurance covering its Exploitation of the Licensed Compounds and Products as is (i) normal and customary in the pharmaceutical industry generally for parties similarly situated and (ii) otherwise required by Applicable Law. 

ARTICLE 10 
 TERM AND
TERMINATION 
 10.1 Term and Termination. This Agreement will become effective on the Effective Date and will continue
until the expiration of all Royalty Terms for all Products under this Agreement, unless earlier terminated in accordance with this Article 10 (Term and Termination) (“Term”). 

10.2 Termination for Convenience. Licensee will have the right to terminate this Agreement in its entirety or on a Product by
Product basis, for any reason, by providing MedImmune at least one hundred and twenty (120) days prior written notice. 
 10.3
Termination for Material Breach. In the event of a material breach by a Party or its Affiliates of this Agreement where such breach has a material adverse effect on the other Party’s rights and obligations under this Agreement, the
other Party will have the right to terminate this Agreement in accordance with this Section 10.3. The non-breaching Party shall provide written notice of such breach to the breaching Party, which notice
will specify the nature of such breach in reasonable detail. If the breaching Party does not (i) cure such breach within sixty (60) days following its receipt of such notice, or (ii) if such breach is not curable within such sixty
(60) day notice period, (a) does not deliver a plan to remedy the breach to the non-breaching Party within thirty (30) days of such notice, (b) or delivers such plan and does not diligently
and in good faith pursues a cure of such breach in accordance with such plan, and/ (c) does not cure such breach within one hundred twenty (120) days of the date of delivery of the notice of breach, then the
non-breaching Party may terminate this Agreement by written notice. Notwithstanding the foregoing, in the event of a good faith dispute as to the existence or cure of a material breach under this Agreement,
including any good faith dispute as to payments due under this Agreement, the relevant cure period with respect thereto will be tolled pending resolution of such dispute in accordance with the Section 11.6 of this Agreement; provided,
that to the extent such dispute relates to non-payment under this Agreement the cure period will only apply with respect to payment of disputed amounts, and not with respect to undisputed amounts. If a
material breach by Licensee relates solely to Flu A Products, Flu B Products or an HLE Product, then this Agreement may be terminated only with respect to Flu A Products (including Flu A Compounds), Flu B Products (including Flu B Compounds) or such
HLE Product, respectively, and shall remain in effect with respect to all other Licensed Products and the Licensed Compounds contained therein. For the avoidance of doubt [***]. 

  
 40 

 10.4 Termination for Insolvency. Each Party will have the right to
terminate this Agreement immediately upon written notice, if: (i) the other Party becomes insolvent; (ii) the other Party files a petition in bankruptcy, or if an involuntary petition in bankruptcy is filed against the other Party and the
other Party consents to such petition or such involuntary petition is not dismissed within ninety (90) days and the other Party (a) fails to assume this Agreement in any such bankruptcy proceeding within thirty (30) days after filing
or (b) assumes and assigns this Agreement to a Third Party; or (iii) a receiver or guardian has been appointed for the other Party who is not discharged within seventy-five (75) days after appointment. 

10.5 Termination for Patent Challenge. MedImmune will have the right to terminate this Agreement by thirty (30) days prior
written notice to Licensee, if Licensee or its Affiliates bring or join any challenge to the validity or enforceability of any MedImmune Patent, MedImmune FluAB Patent, or MedImmune HLE Patent (a “Patent Challenge”). For the
avoidance of doubt, (i) a Patent Challenge does not include Licensee or its Affiliates (a) responding to compulsory discovery, subpoenas or other requests for information in a judicial or arbitration proceeding or
(b) complying with any Applicable Law or a court order; and (ii) the foregoing right of termination shall not apply with respect to any Patent Challenge where the Patent Challenge is based solely on whether a claim therein
qualifies as a Valid Claim that Covers the applicable Product, and is made in defense of a claim first brought by MedImmune against Licensee pursuant to this Agreement.  

10.6 Effects of Termination – General 

(i) Termination Effective Date. The “Termination Effective Date” means the effective date of expiration or termination
of this Agreement as specified in the applicable Section of this Agreement. 
 (ii) Effect of Termination. Except as expressly set
forth the following Section 10.6 (Specific Effects of Termination) and Section 10.9 (Accrued Rights; Surviving Obligations) upon the Termination Effective Date, all rights and obligations of the Parties under this Agreement shall
terminate, and shall be of no further force or effect. 
 (iii) Accrued Obligations. Termination of this Agreement will not release
either Party from any liability (including any payment obligations) that, as of the Termination Effective Date, has already accrued to the other Party or which is attributable to activities prior to such termination. 

10.7 Specific Effects of Termination; Termination by Licensee for Convenience or by MedImmune for Cause. In the event of
termination of this Agreement in its entirety or in respect of a Licensed Product (a) by Licensee in accordance with Section 10.2 (Termination for Convenience) or (b) by MedImmune in accordance with Sections 10.3 (Termination for
Material Breach), 10.4 (Termination for Insolvency), or 10.5 (Termination for Patent Challenge), and MedImmune provides notice that it wishes to continue the Exploitation of one or more Licensed Product(s) that were the subject of such termination,
as specified in such notice, the following provisions shall apply:  
 (i) Subject to the terms of this
Section 10.7, Licensee will grant to MedImmune [***]. 

  
 41 

 (ii) In consideration and as a material condition of the grant of the license in
10.6(i), MedImmune shall pay royalties to Licensee on Net Sales (applied mutatis mutandis) of a Licensed Product Covered by a Valid Claim of a Patent within the Licensee Intellectual Property. Rates are payable depending upon the stage of
development of the most advanced Licensed Product at the time of termination of this Agreement under this Section 10.7 as follows: 
  

			
	 Development Stage
	  	Royalty Rate
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 (iii) The royalties set out above in 10.7(ii) shall be reduced [***] if such Licensed Product is no
longer Covered by a Valid Claim of a Patent within the Licensee Intellectual Property in the applicable country of sale. 
 (iv)
MedImmune shall additionally pay any payments (including royalties) payable to a Third Party as a result of the inclusion of Third Party rights, if any, are included in the license grant in Section 10.7(i). 

(v) The royalty term applicable to this Section 10.6 is the longer of twelve (12) years from First Commercial Sale of Licensed
Product or the expiration of a Valid Claim of Licensee Intellectual Property Covering the applicable Licensed Product. 
 (vi) The
following Sections shall apply mutatis mutandis to MedImmune’s exercise of the license granted and payments due under this Section 10.7: Sections 2.2, 3.4, 5.4 through 5.10, 7.5, 8.6, and 9.5. 

(vii) Licensee shall provide or make available to MedImmune all data, manufacturing data and information Controlled by Licensee, related
to the applicable Licensed Product reasonably requested by MedImmune, at MedImmune’s expense or if Medimmune has terminated pursuant to Sections 10.3, 10.4 or 10.5, at Licensee’s expense, including the ability for MedImmune to purchase
existing stock of Licensed Product from Licensee to ensure continued supply to any ongoing clinical trials. 
 (viii) Licensee will
assign to MedImmune or its designee such Third Party contracts relating solely to the applicable Licensed Product as requested by MedImmune, as permitted under Applicable Law and such Third Party contracts. If a Third Party contract cannot be so
assigned (in whole or in part) Licensee shall sublicense (if contractually permitted), and shall seek permission to assign or sublicense in good faith, if applicable, or otherwise use reasonable efforts to transfer or provide to MedImmune or its
designee the benefit of its rights under such contract relating to the applicable Licensed Product, at MedImmune’s expense or if MedImmune has terminated this Agreement pursuant to Sections 10.3, 10.4 or 10.5, at Licensee’s expense. 

  
 42 

 (ix) Licensee shall assign to MedImmune or its designee any Trademarks (excluding any
corporate Trademark), domain names and websites in each case that are Controlled by Licensee and solely related to the applicable Licensed Product (collectively, “Transferred Trademarks”), to the extent assignable, and if not
assignable, shall license or sublicense such Transferred Trademarks to MedImmune or its designee. MedImmune shall as of the date of the assignment be solely responsible for the prosecution and maintenance of all Transferred Trademarks, and
shall register the assignment agreements relating to these assets with all applicable governmental and non-governmental offices having authority over trademarks and domain names and copyright, at
MedImmune’s expense. 
 (x) Licensee will transfer to MedImmune or its designee(s) any Regulatory Documentation and Regulatory
Approvals solely related to the applicable Licensed Product owned by Licensee including promptly submitting any necessary notices to Governmental Authorities to effect such assignments, at MedImmune’s expense. If Applicable Laws prevent or
delay the transfer of ownership of any such regulatory filing or Regulatory Approval to Licensee or its designee(s), Licensee will grant to MedImmune (and/or its Affiliates or designee(s)) a right of access and reference to such regulatory filing
and Regulatory Approvals for purposes of developing, manufacturing, and commercializing the applicable Licensed Product, and will reasonably cooperate to make the benefits of such regulatory filings and Regulatory Approvals available to MedImmune or
its designee(s) for the Licensed Product, at MedImmune’s expense. 
 10.8 Rights in Bankruptcy. All rights and licenses
granted under or pursuant to this Agreement by Licensee or MedImmune are and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses
of right to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their
rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the
U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual
property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (i) upon any such commencement of a
bankruptcy proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or
(ii) if not delivered under clause (i) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.

 10.9 Accrued Rights; Surviving Obligations. 

(i) Termination or expiration of this Agreement (either in its entirety or in respect of a Product) for any reason shall be without
prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or
expiration of this Agreement. 

  
 43 

 (ii) Without limiting the foregoing, Sections, 5.3(iv), 5.3(v), 5.4 to 5.10 (provided
that such provisions shall survive only with respect to payment obligations accruing prior to the effective date of such termination or expiration), 6.1, 9.1, 9.2, 9.3, 9.4, 10.6 to 10.9, 11.3 to 11.18 and Article 1 (to the extent necessary to give
effect to the surviving provisions) and Article 7 (for the period set forth therein) of this Agreement shall survive the termination or expiration of this Agreement for any reason. 

(iii) If this Agreement is terminated with respect to a Product but not in its entirety, then following such termination the provisions
of this Agreement shall terminate with respect to such Product except as specified in subsection (ii) above. 
 ARTICLE 11 

MISCELLANEOUS 
 11.1
Amendment to Humabs Agreement. Contemporaneously with the execution of this Agreement, MedImmune and Humabs shall execute the amendment to the Humabs Agreement in the form as set forth on Schedule 1. 

11.2 Force Majeure. Neither Party shall be held liable or responsible to the other Party or be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or results from events beyond the reasonable control of the non-performing Party, including fires, floods, earthquakes, hurricanes, embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections, riots, civil
commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party or of any other Person), acts of God or acts, omissions or delays in acting by any
governmental authority (except to the extent such delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement). The non-performing Party shall notify the other Party of such force majeure within [***] after such occurrence by giving written notice to the other Party stating the nature of the event, its anticipated duration and
any action being taken to avoid or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and the non-performing Party shall use commercially
reasonable efforts to remedy its inability to perform. Without limitation to the foregoing, in the event that the suspension of performance continues for [***] after the date of the occurrence and such suspension of performance would constitute a
material breach of this Agreement in the absence of this Section 11.2, the other Party shall have the right to terminate this Agreement pursuant to Section 10.3 without regard to this Section 11.2. 

11.3 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical
information from the United States or other countries that may be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under this
Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate
agency or other governmental entity in accordance with Applicable Law. 

  
 44 

 11.4 Assignment. Neither Party may assign its rights or delegate
its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that
either Party shall have the right, without such consent, (i) to perform any or all of its obligations and exercise any or all of its rights under this Agreement through any of its Affiliates or its or their (sub)licensees (and shall remain
directly liable to the other Party for such performance), and (ii) assign any or all of its rights and delegate any or all of its obligations hereunder to any of its Affiliates or its or their (sub)licensees or to any successor in interest
(whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement relates; provided that a) such Party shall provide written notice to the other Party within [***] after such
assignment or delegation. Any permitted successor of a Party or any permitted assignee of all of a Party’s rights under this Agreement that has also assumed all of such Party’s obligations hereunder in writing shall, upon any such
succession or assignment and assumption, be deemed to be a party to this Agreement as though named herein in substitution for the assigning Party, whereupon the assigning Party shall cease to be a party to this Agreement and shall cease to have any
rights or obligations under this Agreement except that the assigning Party shall remain bound by Article 7 as if remaining a party to this Agreement. For clarity, no such assignment shall release the assigning Party from any liability accruing prior
to such assignment. All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns
of such Party; provided that such Party, if it survives, shall remain jointly and severally liable for the performance of such delegated obligations under this Agreement. Any attempted assignment or delegation in violation of this
Section 11.4 shall be void and of no effect. Notwithstanding any other provision of this Section 11.4, the terms of this Agreement may be varied, amended or modified or this Agreement may be suspended, cancelled or terminated without the
consent of any assignee or delegate that is not deemed pursuant to the provisions of this Section 11.4 to have become a party to this Agreement. 

11.5 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future
law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (i) such provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision
or by its severance herefrom and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in intended effect to such
illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal,
invalid or unenforceable in any respect. 
 11.6 Dispute Resolution. 

(i) Except as provided in Sections 5.10, 11.6(viii) and 11.11, if a dispute arises between the Parties relating to this Agreement
or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during a period of
[***]. Any final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties. 

  
 45 

 (ii) If such Senior Officers are unable to resolve any such Dispute within such [***]
period, then the Dispute shall be finally settled by arbitration administered by the American Arbitration Association (the “AAA”) under its Commercial Arbitration Rules except as modified in this Agreement. The panel shall be
comprised of three (3) [***] (the “Arbitrators”). Each of Licensee and MedImmune shall promptly appoint one (1) Arbitrator, which appointment shall in no event be made later than [***] after the commencement of the arbitration.
The third Arbitrator, who shall serve as the presiding arbitrator, shall be appointed promptly by mutual agreement of the two party-appointed Arbitrators, but in no event later than [***] after the date of the second Arbitrator’s appointment.

 (iii) The Arbitrators shall determine what discovery will be permitted, consistent with the goal of achieving an efficient and
economical resolution of the dispute; provided that the Arbitrators shall permit such discovery as they deem necessary to permit each Party the opportunity to fairly present its claims and defenses. The seat, or legal place of arbitration,
shall be in [***] and the Parties shall use reasonable efforts to expedite the arbitration if requested by either Party. The language of the arbitration shall be English. 

(iv) The Arbitrators shall, within [***] after the conclusion of the arbitration hearing, issue a written award and reasoned decision
describing the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. This time limit may be extended by the Arbitrators for good cause shown, or by mutual agreement of the Parties. The
decision or award rendered by the Arbitrators shall be final and non-appealable, and judgment may be entered upon it in any court of competent jurisdiction. The Arbitrators shall be authorized to award
compensatory damages, but shall not be authorized to reform, amend, modify or change this Agreement or any other agreements contemplated hereunder. 

(v) Each Party shall bear its own counsel fees, costs, and disbursements arising out of the dispute resolution procedures described in
this Section 11.6, and shall pay an equal share of the fees and costs of the Arbitrators, and all other general fees related to any arbitration described in Section 11.6(ii), as applicable; provided, however, the Arbitrators shall
be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing Party reimbursement for its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses, photocopy charges,
or travel expenses), or the fees and costs of the Arbitrators, as applicable. Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding described in Section 11.6(ii) is pending under this
Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of such pending arbitration proceeding. 

(vi) Nothing contained in this Agreement shall preclude any Party from seeking interim or other equitable or provisional relief from a
court of competent jurisdiction to preserve the status quo or prevent irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding. 

  
 46 

 (vii) The existence and content of the arbitral proceedings and any rulings or award
of the Arbitrators shall be deemed Confidential Information of both Parties under Article 7 except to the extent that disclosure is necessary to protect or pursue a legal right, or to enforce or challenge an award. Notwithstanding anything to the
contrary, either Party may disclose matters relating to the arbitration or the arbitral proceedings where necessary for the preparation or presentation of a claim or defense in such arbitration. 

(viii) Notwithstanding the foregoing, in the event that a Dispute arises with respect to the validity, scope, enforceability,
inventorship or ownership of any Patent, Trademark or other intellectual property rights, either Party may bring an action in a court of competent jurisdiction in accordance with this Agreement (or, as applicable, with any patent or trademark
authority of competent jurisdiction) to resolve any such Dispute, and no such Dispute shall be subject to arbitration pursuant to Section 11.6. 

11.7 Governing Law and Service. 

(i) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware excluding any
conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the United
Nations Convention on Contracts for the International Sale of Goods. 
 (ii) Service. Each Party further agrees that service of any
process, summons, notice or document by registered mail to its address set forth in Section 11.8(ii) shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

11.8 Notices. 
 (i)
Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if
delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in
Section (ii) or to such other address as the Party to whom notice is to be given may have provided to the other Party in accordance with this Section (i). Such Notice shall be deemed to have been given as of the date delivered by hand or
transmitted by facsimile (with transmission confirmed) or on the second Business Day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a
hard copy delivered as soon as practicable thereafter. This Section (i) is not intended to govern the day-to-day business communications necessary between the
Parties in performing their obligations under the terms of this Agreement. 

  
 47 

 (ii) Address for Notice. 

If to Licensee, to: 
 [***] 

with a copy (which shall not constitute notice) to: 

[***] 
 If to MedImmune, to:

 [***] 
 with a copy (which
shall not constitute notice) to: 
 [***] 

11.9 Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth and constitutes the
entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded hereby. Each Party
confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on the Parties unless in writing and duly
executed by authorized representatives of both Parties. In the event of any inconsistencies between this Agreement and any schedules or other attachments hereto, the terms of this Agreement shall control. Except to the extent expressly provided
herein, the Prior CDA shall continue in full force and effect in accordance with its terms.  
 11.10 English
Language. This Agreement shall be written and executed in and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version
thereof and in the event of any conflict in interpretation between the English version and such translation, the English version shall control. 

11.11 Equitable Relief. Each Party acknowledges and agrees that the restrictions set forth in [***] Articles 6 and 7 are
reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of
such Section or Articles may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach or threatened breach of any provision of such Section or Articles, the non-breaching Party shall be authorized and entitled to obtain to seek from any court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable
accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other rights or remedies to which such non-breaching Party may be
entitled in law or equity. Both Parties agree to waive any requirement that the other (i) post a bond or other security as a condition for obtaining any such relief and (ii) show irreparable harm, balancing of harms, consideration of the
public interest or inadequacy of monetary damages as a remedy. Nothing in this Section is intended or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this
Agreement. Additionally, in the event of a breach of [***], the Parties acknowledge that MedImmune may be added as a party to any action to claim equitable relief. If Licensee does not wish to pursue its Sublicensee, MedImmune will be permitted to
step in and take control of such action at MedImmune’s own cost and expense. 

  
 48 

 11.12 Waiver and Non-Exclusion of
Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf
of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or
failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth
herein. 
 11.13 No Benefit to Third Parties. Except as provided in Article 9, the covenants and agreements set forth in this
Agreement are for the sole benefit of the Parties hereto and their successors and permitted assigns and they shall not be construed as conferring any rights on any other Persons. 

11.14 Further Assurance. Each Party shall duly execute and deliver or cause to be duly executed and delivered, such further
instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement
or to carry out more effectively the provisions and purposes hereof or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

11.15 Relationship of the Parties. It is expressly agreed that MedImmune, on the one hand and Licensee, on the other hand, shall
be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MedImmune, on the one hand, nor Licensee, on the other hand, shall have the authority to make any
statements, representations or commitments of any kind or to take any action, that will be binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees of such Party and not
of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and expense of such first Party. 

11.16 References. Unless otherwise specified, (i) references in this Agreement to any Article, Section or Schedule shall
mean references to such Article, Section or Schedule of this Agreement, (ii) references in any Section to any clause are references to such clause of such Section and (iii) references to any agreement, instrument or other document in this
Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect at the relevant time of reference
thereto. 
 11.17 Construction. Except where the context otherwise requires, wherever used, the singular shall include the
plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. 

  
 49 

 
The headings and captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any
provision contained in this Agreement. The term “including,” “include,” or “includes” as used herein shall not be interpreted as limiting the generality of any description following such term. “Or” is used in
its inclusive sense (i.e., “and/or”) unless the context clearly requires otherwise. No rule of strict construction shall be applied against either Party. 

11.18 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile, PDF format via email or other electronically transmitted signatures and such signatures shall be deemed to bind each Party
hereto as if they were original signatures. 
 [SIGNATURE PAGE FOLLOWS.] 

  
 50 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the Effective Date. 

 

									
	MEDIMMUNE, LLC	 		  	VIR BIOTECHNOLOGY, INC.
					
	By:	 	 /s/ Bahija Jallal
	 		  	By:	  	 /s/ George Scangos

	Name:	 	Bahija Jallal	 		  	Name:	  	George Scangos
	Title:	 	President, MedImmune	 		  	Title:	  	Chief Executive Officer

  
 Signature Page to License
Agreement 

 Schedule 1 

Amendment to Humabs Agreement 

September 7, 2018 
 [***] 

MedImmune, Inc. 
 One MedImmune Way 

Gaithersburg, MD 20878 
 Re: Amendment No. 6 to Sub-Licence and Collaboration Agreement 
 Dear [***], 

As you know, Humabs Biomed SA (“Humabs”), a wholly owned subsidiary of Vir Biotechnology Inc., and MedImmune, LLC
(“MedImmune”) are parties to that certain Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended (the “Agreement”). By this letter amendment (this
“Amendment”), Humabs and MedImmune agree to amend the Agreement as described below, effective as of the date first set forth above. 

Subclause (i) of Section 2.4 of the Agreement, as amended by Amendment No. 4 to the Sub-Licence and
Collaboration Agreement, is hereby amended and replaced in its entirety to read as follows: 
 “(i) the activities of the Acquiror or
its Affiliates (including Humabs to the extent Humabs survives such acquisition as a separate entity) with respect to any product, product candidate, device, or service (including the making, using, selling, offering for sale, importing, or
otherwise developing, commercializing, or exploiting thereof), prior to the date of such Change of Control or thereafter if such product, product candidate, device, or service was not developed in a material respect through the use of any Humabs
Antibody Technology Controlled by Humabs prior to or as of the date of such Change of Control, or...” 
 Clause 9.7.2 of the Agreement is hereby
amended and replaced in its entirety to read as follows: 
 “A Receiving Party may disclose the existence and terms of this Agreement
and the Confidential Information of the Disclosing Party to its attorneys and advisors and to potential acquirers in connection with a potential consolidation, acquisition, merger or similar transaction and to existing and potential investors or
lenders of the Receiving Party, as a part of their due diligence investigations, and/or to potential licensees and/or to 

 
potential collaborators and/or to permitted assignees, in each case under a written agreement to keep the terms of this Agreement confidential and to use the Confidential Information solely for
the purpose permitted pursuant to this clause.” 
 Any capitalized terms used herein and not otherwise defined herein will have the meaning ascribed in
the Agreement. Except as expressly set forth herein, all of the terms of the Agreement will remain in full force and effect. 
 Please indicate
MedImmune’s agreement to the foregoing by having an authorized representative of MedImmune sign this Amendment in the appropriate signature line below. 
  

							
	Sincerely,	 		  	 Agreed and accepted:

MedImmune, LLC

				
	Filippo Riva	 		  	By:	  	  

	Managing Director	 		  	Name:	  	  

		 		  	Title:	  	  

		 		  	Date:	  	  

 Schedule 2 

Not Used 

 Schedule 3 

[***] 

 Schedule 4 

[***] 

 Schedule 5 

In-License Agreements 

[***]. 
 March 10, 2012.
Sub-License and Collaboration Agreement between MedImmune and Humabs BioMed, as amended. 

 Schedule 6 

Not Used 

 Schedule 7 

MedImmune Intellectual Property 
 A.
MedImmune Patents [***] 

 B. MedImmune FluAB Patents [***] 

 C. MedImmune HLE Patents 

[***] 

 Schedule 8 

MedImmune Know-How to be Transferred to Licensee 

In all cases, documents may have [***] 

 Schedule 9 

MedImmune Regulatory Documentation 
 [***]EX-10.21

 Exhibit 10.21 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 SECOND REVISED AND
RESTATED MASTER EXCLUSIVE LICENSE AGREEMENT 

BETWEEN OHSU AND VIR BIOTECHNOLOGY, INC. 

 

							
	 1.
	 	 BACKGROUND
	  	 	2	 
	 2.
	 	 DEFINITIONS
	  	 	2	 
	 3.
	 	 GRANT OF RIGHTS
	  	 	8	 
	 4.
	 	 PAYMENTS
	  	 	10	 
	 5.
	 	 SUBLICENSING
	  	 	13	 
	 6.
	 	 COMMERCIALIZATION
	  	 	13	 
	 7.
	 	 RESTRICTIONS
	  	 	14	 
	 8.
	 	 BOOKS, RECORDS AND REPORTS
	  	 	15	 
	 9.
	 	 CONFIDENTIAL INFORMATION
	  	 	15	 
	 10.
	 	 PROSECUTION, DEFENSE AND MAINTENANCE OF PATENTS
	  	 	16	 
	 11.
	 	 PATENT ENFORCEMENT
	  	 	17	 
	 12.
	 	 REPRESENTATIONS, WARRANTIES AND DISCLAIMERS
	  	 	18	 
	 13.
	 	 INSURANCE
	  	 	19	 
	 14.
	 	 INDEMNIFICATION
	  	 	19	 
	 15.
	 	 TERM AND TERMINATION
	  	 	20	 
	 16.
	 	 GENERAL PROVISIONS
	  	 	22	 

 APPENDIX A: COMMERCIAL DEVELOPMENT PLAN 

APPENDIX B: ANNUAL UPDATE TO COMMERCIAL DEVELOPMENT PLAN 

APPENDIX C: QUARTERLY REPORT 
 APPENDIX D: FORM OF
TECHNOLOGY ADDENDUM 
 APPENDIX E: FORM OF MATERIAL TRANSFER ADDENDUM 

APPENDIX F: STOCK PURCHASE AGREEMENT 

  

					
	Confidential	  		  	

 SECOND REVISED AND RESTATED MASTER EXCLUSIVE LICENSE AGREEMENT 

This Second Revised and Restated Master Exclusive License Agreement (this “Agreement”), is between the Oregon Health & Science
University, having offices at 0690 SW Bancroft Street, Portland, Oregon 97239 (“OHSU”), and Vir Biotechnology, Inc., a Delaware corporation with a principal business address of 499 Illinois Street, San Francisco, California 94158
(“Licensee”). OHSU and Licensee are herein referred to each as a “Party” and collectively as the “Parties.” This Agreement shall replace in its entirety the Revised and Restated Master Exclusive License Agreement
between the Parties, effective as of June 22, 2012 (the “Effective Date”). The Effective Date for this Agreement shall remain the same as for the Revised and Restated Master Exclusive License Agreement. 

 

	1.	 BACKGROUND 

  

	1.1	 OHSU has created certain inventions and discoveries generally described in OHSU Technology #’s
[***] all of which are related to cytomegalovirus (“CMV”) vectors for use in vaccine development (each an “Invention” and collectively the “Inventions”) all of which has been licensed to Licensee
under this Agreement through the execution of ten previous Technology Addendums and the ones attached herein. 

  

	1.2	 OHSU and TomegaVax, Inc., a wholly owned subsidiary of Licensee, entered into that certain Revised and
Restated Master Exclusive License Agreement dated and effective June 22, 2012 and certain Technology Addenda thereunder (the “License Agreement”) whereby such License Agreement is under the control of Licensee (Licensee
acquired TomegaVax, Inc on September 12, 2016) and therefore being restated in Licensee’s name for purposes of this Agreement. 

  

	1.3	 OHSU and Licensee mutually desire to revise and restate the License Agreement. 

 

	1.4	 OHSU intends to include, certain additional OHSU inventions, discoveries,
know-how and patent rights based on the composition or use of CMV vaccine vectors to this Agreement through the execution of addendums (each particular addendum herein referred to as a “Technology
Addendum”). 

  

	1.5	 OHSU may, from
time-to-time include certain biological materials related to the Inventions, to this Agreement through the execution of addendums (each particular addendum herein
referred to as a “Material Transfer Addendum”). One Material Transfer Addendum is attached herein. 

  

	1.6	 OHSU desires the Inventions to be utilized for the public benefit to the fullest extent possible.

  

	1.7	 Licensee intends to bring together the scientific and business talent, facilities and capital to develop
and market products and processes based upon the Inventions. 

  

	1.8	 Licensee wishes to obtain from OHSU, and OHSU is willing to grant to Licensee, a license to exploit the
Inventions subject to the terms and conditions set forth below. 

  

	2.	 DEFINITIONS 

  

	2.1	 “Affiliate” means any entity that controls, is controlled by or is under common control
with Licensee, where “control” means beneficial ownership of more than 50% of the outstanding voting securities of an entity, the right to receive 50% or more of the profits or earnings, or the ability otherwise to elect a majority of the
board of directors or other managing authority. 

  

					
	Confidential	  	2	  	

	2.2	 “BLA” means the Biologics License Application submitted to the FDA or the equivalent
application or filing submitted to any regulatory authority outside of the United States for Regulatory Approval. 

  

	2.3	 “Change of Control” means (a) the acquisition, either directly or indirectly,
through one or a series of transactions by any third party of more than fifty percent of the voting stock of licensee; (b) any merger or consolidation involving Licensee that requires a vote of the stockholders of Licensee; or (c) the
transfer to any third party of all or substantially all the assets of Licensee relating to the subject matter of this Agreement. 

  

	2.4	 “Clinical Material” shall have the meaning set forth in each Material Transfer
Addendum, if applicable to the rights granted thereunder. 

  

	2.5	 “Clinical Trial” means a human clinical trial of a Licensed Product in the Field of Use
sponsored by Licensee or an Affiliate or Sublicensee or partner thereof anywhere in the world. 

  

	2.6	 “Collaboration Agreement” means an agreement between OHSU and another academic or
nonprofit institution providing for the performance of collaborative research involving the practice of any invention claimed by the Patent Rights by [***] and/or OHSU employees working under their direction at OHSU and one or more employees of such
other academic or nonprofit institution. 

  

	2.7	 “Commercialize or Commercialization” means any and all activities directed to
manufacturing, marketing and sell marketing, promoting, distributing, offering for sale and selling a Licensed Product. For clarity, it excludes Develop and Development. 

 

	2.8	 “Commercial Development Plan” means a written plan submitted by Licensee describing the
details of how and when Licensee will commercially develop and exploit the Licensed Technologies, attached hereto in Appendix A, and as updated pursuant to Section 6.2 of the Agreement. 

 

	2.9	 “Confidential Information” means all information and materials provided by one Party
(“Disclosing Party”) to the other (“Recipient”) and designated as confidential by Disclosing Party when provided. The term “Confidential Information” does not include any information or materials that the
Recipient demonstrates (a) is or becomes part of the public domain through no fault of the Recipient or anyone receiving the Confidential Information from Recipient; (b) was already known to Recipient prior to disclosure as demonstrated
through adequate written records; (c) is disclosed to Recipient by a third party who has the right to make such disclosure; or (d) through adequate written records to have been developed independently of knowledge of or access to the
Confidential Information. The specific terms and conditions of this Agreement are Confidential Information of both Parties, but the existence of the Agreement and Field of Use are not. 

 

	2.10	 “Develop and Development” means all activities in connection with product development,
including research, preclinical development, clinical development, development of the Licensed Technology, laboratory work, and development related to Licensed Technology, as are customary in the pharmaceutical industry. 

  

					
	Confidential	  	3	  	

	2.11	 “Developed Country” means any country that is not identified as a Least Developed
Country as defined herein. 

  

	2.12	 “FDA” means the United States Food and Drug Administration or any successor agency.

  

	2.13	 “Field of Use” means all fields of use for all Licensed Technology except if otherwise
defined in any Technology Addendum entered into by the Parties. 

  

	2.14	 “Improvement” means any invention disclosed to OHSU Technology Transfer that directly
relates to or is derived from the Patent Rights, or uses or incorporates the Patent Rights and was conceived and reduced to practice prior to the expiration of the Improvement Option Grant Term either: 

 

	 	(1)	 at OHSU solely or jointly by [***] and/or one or more of those OHSU employees working under their direction at
the time the relevant invention was conceived and reduced to practice; or 

  

	 	(2)	 pursuant to a Collaboration Agreement, solely or jointly by [***] and/or one or more of those OHSU employees
working under their direction at OHSU at the time the relevant invention was conceived and reduced to practice, on the one hand, and one or more employees of such other academic or nonprofit institution, on the other hand. 

For purposes of this Section 2.14, an OHSU employee “under their [***] direction” shall mean an OHSU employee who
(i) functionally reports to either of them or a subordinate employees working on their behalf, and (ii) works in their laboratory under their or a subordinate employees’ supervision working on their behalf. 

 

	2.15	 “Improvement Option Grant Term” means the period of [***] beginning on the final
signature date of this Second Revised and Restated Exclusive Master License Agreement. 

  

	2.16	 “IND” means an Investigational New Drug Application filed with the FDA or the
equivalent application or filing submitted to any regulatory authority outside of the United States necessary to commence a Clinical Trial in such jurisdiction. 

 

	2.17	 “Indication” means the use of a Vir License Product for the treatment or prevention of
a particular disease or infection, e.g. prostate cancer, Hepatitis B, mycobacterium Tuberculosis, HIV, and others. 

  

	2.18	 “Inventors” means the individuals listed as inventors on any patent application or
issued patent included within the Patent Rights. 

  

	2.19	 “Know-How” shall have the meaning set forth in
each Technology Addendum. 

  

	2.20	 “Least Developed Countries” means each country identified as a low-income economy by the World Bank Group and by the United Nations on their respective websites at the time the Licensed Product is transferred. 

 

	2.21	 “Licensed Materials” means the Licensed Materials listed in each applicable Material
Transfer Addendum. 

  

	2.22	 “Licensed Product” means (a) any method, procedure, service or process that
incorporates, uses, used, is covered by, infringes or would infringe any Licensed Technology but for the exception in 35 U.S.C. §271(e)(1), or similar exception in the U.S. or foreign jurisdictions; and (b) any

  

					
	Confidential	  	4	  	

	 	
apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any Licensed Technology but for the exception in 35 U.S.C.
§271(e)(1), or similar exception in the U.S. or foreign jurisdictions. 

  

	2.23	 “Licensed Technology” means a pending or issued claim of the Patent Rights.

  

	2.24	 “NDA” means the New Drug Application filed with the FDA or the equivalent application
or filing submitted to any regulatory authority outside of the United States for Regulatory Approval. 

  

	2.25	 “Net Sales” means the gross invoiced amount charged by Licensee, its Affiliates and/or
its Sublicensees, for the sales of a Licensed Product, less any of the following items that are itemized on the relevant invoice or which Licensee [***]: 

[***] 
 The deductible items
listed in sub-clauses (a)-(f) above shall be either (i) included as line items on the invoice, or (ii) otherwise documented as being specifically attributable to actual sales of Licensed Products in
accordance with United States Generally Accepted Accounting Principles (GAAP) or International Financing Reporting Standards (IFRS), as applicable, consistently applied throughout the organization of either Licensee or any Sublicensee. [***]. If
Licensee or Sublicensee determines the resale price for subsequent transfers of Licensed Product, then Net Sales will be calculated based on the resale invoiced amount. If Licensee or Sublicensees sell the Licensed Products with any other goods or
services, Net Sales will be calculated based on the [***]. Net Sales accrue at the first of delivery or invoice. 
 Notwithstanding the
foregoing, Licensee and Sublicensee may transfer Licensed Products for the following purposes without generating a Net Sale: (i) to a contract research organization solely for Development for the direct benefit of the Licensee or Sublicensee,
and (ii) to a third-party solely to demonstrate the Licensed Products potential to customers or partners; (iii) to a third-party solely for purposes related to obtaining Regulatory Approval; or (iv) in commercially reasonable amounts
for use as sales samples. 
 If any Licensed Product is sold as a Combination Product (“Combination Product” shall mean a Licensed
Product and any other clinically active therapeutic or prophylactic ingredient, mechanism or device), the Net Sales from the Combination Product, for the purposes of determining royalties, shall be determined by multiplying the Net Sales of the
Combination Product during the applicable calendar quarter, by the fraction, A/(A+B), where A is [***], in each case during the applicable calendar quarter or, if sales of both the Sole Compound Product and the other active compounds or active
ingredients did not occur in such period, then in the most recent Calendar Quarter in which sales of both occurred. If such [***], Net Sales for the purposes of determining milestones and royalties shall be calculated by multiplying the Net Sales of
the Combination Product by the fraction of C/(C+D) where C is the [***] shall be applicable to the Country of Sale. In such event, Licensee shall [***] in the Combination Product, and shall [***]. If OHSU in good faith does not agree with such
determination, OHSU shall give Licensee written notice of its disagreement within [***] after receiving the relevant report pursuant to Section 8.2, and the matter shall be submitted for final and binding resolution pursuant to the
Section 16.7. “Sole Compound Product” shall mean a product containing no active compounds or active ingredients other than a single CMV vector vaccine. In the case of any sale or other disposal for value, such as barter or
counter-trade, of Licensed Product, or part thereof, other than 

  

					
	Confidential	  	5	  	

 
in an arm’s length transaction exclusively for cash, Net Sales shall be calculated as above on the value of the non-cash consideration received or the
fair market price (if higher) of the Licensed Product in the country of sale or disposal, as determined in accordance with Applicable Accounting Standards. 

Provided that the Related Parties aren’t the end user, Sales between or among Licensee and its Related Parties shall be excluded from the
computation of Net Sales, but Net Sales shall include sales to the first third party thereafter by Licensee or its Related Parties. 
  

	2.26	 “OHSU-Controlled Improvement” means an Improvement with respect to which OHSU possesses
the power and authority, whether arising by ownership, license, or other authorization, to grant a license without violating the terms of any written agreement with any third party. For purposes of clarity, OHSU-Controlled Improvements specifically
exclude: (a) [***] at OHSU that is [***]; and (b) any Improvement described in Section 2.14 (2) that is invented pursuant to a Collaboration Agreement that does not allow OHSU to grant licenses to such Improvement without the other
party’s consent. 

  

	2.27	 “Patent Costs” means all out-of-pocket costs and expenses incurred by OHSU in connection with the preparation, filing, prosecution, defense, including interference and opposition proceedings, and maintenance of the Patent Rights.

  

	2.28	 “Patent Rights” shall have the meaning set forth in each Technology Addendum.

  

	2.29	 “Phase 1 Clinical Trial” means a Clinical Trial in any country that is intended to
initially determine the metabolism and pharmacologic actions of the drug, side effects associated with increasing doses and/or to gain early evidence of the effectiveness of a pharmaceutical product for a particular indication or indications in
normal volunteer subjects or in patients with the disease or indication under study or that would otherwise satisfy requirements of 21 CFR 312.21(a), or its foreign equivalent. 

 

	2.30	 “Phase 2 Clinical Trial” means a Clinical Trial in any country that is intended to
initially evaluate the effectiveness of a pharmaceutical product for a particular indication or indications in patients with the disease or indication under study or that would otherwise satisfy requirements of 21 CFR 312.21(b), or its foreign
equivalent. 

  

	2.31	 “Phase 3 Clinical Trial” means a pivotal Clinical Trial in any country for which the
results of could be used to establish safety and efficacy of a pharmaceutical product as a basis for a NDA or BLA that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent. 

 

	2.32	 “Reasonably Diligent Efforts” means the application of a level of human and financial
resources, efforts and urgency to Develop and Commercialize Licensed Products consistent with Licensee’s practices in pursuing the Development and Commercialization of its other high-value products in light of the Licensed Product’s
characteristic features, target indication, competitiveness and sales volume, but in no event less than the level commonly applied by other pharmaceutical companies to their own high-value products of a similar nature. 

 

	2.33	 “Related Parties” means any Sublicensee or an Affiliate. 

 

	2.34	 “Regulatory Approval” means the approval from any regulatory authority such as the FDA
or a foreign equivalent regulatory authority necessary for Commercialization of a Licensed Product. 

  

					
	Confidential	  	6	  	

	2.35	 “Royalty Term” means, with respect to each Vir Licensed Product sold in a particular
country (the “Country of Sale”), the period beginning on the date of the first Net Sale of such Vir Licensed Product in the Country of Sale and ending on the latest to occur of: (i) the expiration of the last to expire of the
Patent Rights in the Country of Sale containing a Valid Claim that would, in the absence of a license under the Patent Rights, be infringed by the manufacture, use, sale, offer for sale or import of such Vir Licensed Product in the Country of Sale;
(ii) if the Vir Licensed Product is manufactured in a country other than the Country of Sale (such other country, the “Country of Manufacture”) and the manufacture, use, sale, offer for sale or import of such Vir Licensed
Product in the Country of Manufacture would, in the absence of a license under the Patent Rights, infringe a Valid Claim of the Patent Rights in the Country of Manufacture, the expiration of the last to expire of the Patent Rights in the Country of
Manufacture containing a Valid Claim that would, in the absence of a license under the Patent Rights, be infringed by the manufacture, use, sale, offer for sale or import of such Licensed Product in the Country of Manufacture; and (iii) the
tenth (10th) anniversary of the first Net Sale of such Vir Licensed Product in such Country of Sale. 

  

	2.36	 “Sublicense” means a license granted by Licensee to a third party for all or a portion
of the rights granted to the Licensee under the Licensed Technology, provided that such license is granted in accordance with Article 5. 

  

	2.37	 “Sublicense Revenue” means all amounts due and payable to Licensee and its Affiliates
from any Sublicensee, in consideration for a Sublicense for the rights granted to the Sublicensee in the Licensed Technology, whether received in cash or any other form of consideration, other than amounts received as a royalty for sales of Licensed
Products generating royalty payments (whether paid in the form of a percentage of net sales or as a percentage of profits of any such Sublicensee). Sublicense Revenue includes [(***] due and payable in consideration of any Sublicense of the rights
granted hereunder in and to the Licensed Technology, (b) [***], and (c) [***]. Sublicense Revenue will not include [***]. Notwithstanding the foregoing, to avoid double-counting of payments to OHSU, Licensee shall have the right to credit any
milestone payments paid to OHSU pursuant to Section 4.2 against any Sublicensing Revenues arising from payments received by Licensee from a Sublicensee for achievement of the equivalent milestone event, prior to the calculation of the
Sublicense Fees due OHSU. By way of example only, [***], if Licensee receives Sublicensing Revenue from a Sublicensee [***] then OHSU will receive a payment of [***]. 

 

	2.38	 “Sublicensees” means any person or entity that directly or indirectly obtains a
Sublicense in or to Licensed Technology from Licensee or a Sublicensee in order to Develop and/or Commercialize a Licensed Product, including by an agreement not to assert rights, other than solely from the purchase of Licensed Product. For the
avoidance of doubt, Licensee’s third-party contractors (e.g. manufacturers, contract manufacturing organizations, vendors, clinical site and investigator, and contract research organizations) shall not be considered Sublicensees under this
definition. 

  

	2.39	 “Term” means the period beginning on the Effective Date and, subject to earlier
termination under Section 15, will expire upon the later of either (i) the expiration of the last-to-expire Valid Claim of the Licensed Technology or
(ii) ten (10) years after the last Technology Addendum Effective Date. 

  

	2.40	 “Valid Claim” means a claim of an issued patent that has not lapsed, expired, been
canceled, or become abandoned, and has not been held invalid by a court or other appropriate body of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise. 

  

					
	Confidential	  	7	  	

	 	The term “Valid Claim” shall also include a claim of a pending patent application which has not been pending for a period of more than [***] from the date of the first presentation of claims for examination on
the merits (i.e. first office action) of that patent application. 

  

	2.41	 “Vir Licensed Product” means a prophylactic or therapeutic product that incorporates
some or all of the Licensed Products. 

  

	3.	 GRANT OF RIGHTS 

 

	3.1	 Licenses 

  

	 	(a)	 Exclusive Patent License. Subject to the terms and conditions of this Agreement and Licensee’s
compliance therewith, unless otherwise stated in one or more Technology Addendum, OHSU grants to Licensee and its Affiliates an exclusive, worldwide license, with the right to grant Sublicenses as set forth below under the Patent Rights, to make,
have made, use, distribute, have distributed, research, improve, offer to sell, sell, have sold, and import Licensed Products for the Field of Use. 

  

	 	(b)	 Non-Exclusive Know-How
License. Subject to the terms and conditions of this Agreement and Licensee’s compliance therewith, OHSU grants to Licensee a nonexclusive, worldwide license, with the right to grant Sublicenses as set forth below, under the Know-How to make, have made, use, distribute, have distributed, research, improve, offer to sell, sell and import Licensed Products for the Field of Use. OHSU has made the
Know-How reasonably available to Licensee on an “AS IS, WHERE IS” basis. OHSU has no other obligation with respect to the Know-How. 

 

	 	(c)	 Sublicense. Licensee will have the right to grant Sublicenses through multiple tiers under the rights
conveyed in Sections 3.1(a) and (b), and 3.3 as set forth in Section 5. 

  

	 	(d)	 Limited License. OHSU has not authorized any products or processes other than Licensed Products,
including Vir Licensed Product, made, used, sold and imported in compliance with this Agreement. All conveyances of the rights licensed in this Section 3.1, including Sublicenses, assignments and transfers will be consistent with the terms and
conditions of this Agreement or will be null and void. 

  

	3.2	 Option to Improvements. 

 

	 	(a)	 Subject to the terms and conditions of this Agreement and Licensee’s compliance therewith, OHSU hereby
grants Licensee an exclusive option to incorporate OHSU rights in OHSU-Controlled Improvements under this Agreement (the “Improvement Option”) reserving to OHSU, in each case, the retained rights under Section 3.4 below.
OHSU shall notify Licensee in writing of each OHSU-Controlled Improvement that is disclosed to OHSU within [***] of such disclosure to OHSU, which notice (an “OHSU Notice”) shall include a copy of the relevant written disclosure of
the OHSU-Controlled Improvement to OHSU describing the OHSU-Controlled Improvement. On an OHSU-Controlled Improvement-by-OHSU-Controlled Improvement basis, Licensee may
exercise the Improvement Option with respect to a particular OHSU-Controlled Improvement by delivering written notice of such exercise, which notice shall identify such OHSU-Controlled Improvement, to OHSU (“Exercise Notice”) no
later than [***] after the date Licensee receives the applicable OHSU Notice (the “Option Period”). 

  

					
	Confidential	  	8	  	

	 	(b)	 At Licensee’s request during the Option Period for an OHSU-Controlled Improvement, OHSU shall make effort
to (i) answer reasonable questions relating to such OHSU-Controlled Improvement and (ii) provide to Licensee data relating thereto for assessment by Licensee, with all such information provided pursuant to this section constituting
Confidential Information of OHSU. Notwithstanding any other provision of this Agreement, Licensee may not share any of such information provided pursuant to this section with any third party without prior written consent of OHSU.

  

	 	(c)	 If Licensee exercises the Improvement Option for an OHSU-Controlled Improvement, the Parties shall have [***]
from the date of delivery of the applicable Exercise Notice to OHSU to conclude the negotiation of a Technology Addendum with respect to such OHSU-Controlled Improvement (the “Negotiation Period”). The Negotiation Period may be
extended by mutual written consent of the Parties. 

  

	 	(d)	 [***] related to the OHSU-Controlled Improvement during the Option Period and the Negotiation Period. If at the
end of the Option Period or the Negotiation Period, the Parties are unable to agree upon the terms of the Technology Addendum or if Licensee elects not to exercise its Improvement Option or terminates the negotiation in writing prior to the end of
the Negotiation Period in accordance with Section 16.1, Licensee shall [***] for the OHSU-Controlled Improvement for which negotiations have terminated. 

  

	 	(e)	 If Licensee fails to exercise the Improvement Option with respect to an OHSU-Controlled Improvement prior to
expiration of the Option Period, or if Licensee exercises the Improvement Option prior to expiration of the Option Period but the Parties are unable to conclude a Technology Addendum with respect to such OHSU-Controlled Improvement prior to
expiration or early termination of the Negotiation Period, OHSU is free to license its rights in such OHSU-Controlled Improvement to any third party without obligation to Licensee. 

 

	3.3	 Material Transfer. From
time-to-time during the Term of this Agreement, OHSU may, at its sole election, transfer Licensed Materials to Licensee for use within the scope of an executed Material
Transfer Addendum. OHSU’s obligations to transfer any Licensed Materials is contingent upon (i) the execution of a Material Transfer Addendum and Licensee’s compliance with this Agreement and such Material Transfer Addendum;
(ii) the availability of Licensed Materials, i.e. OHSU has sufficient quantities to transfer Licensed Materials such that OHSU’s continued and/or future use of Licensed Materials is not impeded by the supply of such Licensed Materials to
Licensee; (iii) Licensee demonstrates that it has obtained all rights required to allow OHSU to transfer such Licensed Materials to Licensee under a Material Transfer Addendum for the intended use, including the right to transfer and/or
Sublicense such Licensed Material to third parties for Development and/or Commercialization; (iv) the Licensed Materials are exclusively owned by OHSU and OHSU has an unencumbered right to transfer the Licensed Material, unless Licensee has
fulfilled its obligations under Section 3.3 (iii) and OHSU has been released of any such encumbrance allowing for such transfer; and /or (v) all OHSU creators of such Licensed Materials approve of the transfer of each subject Licensed
Material to Licensee. 

  

	3.4	 Retained Rights. 

 

	 	(a)	 OHSU reserves the right to (i) practice and have practiced the Licensed Technologies for non-commercial research and education purposes, including granting nonexclusive licenses for non-commercial research and education purposes and distributing biological and
other materials related to the Licensed Technologies to other universities, academic 

  

					
	Confidential	  	9	  	

	 	
institutions and non-profit research organizations; (ii) publish any scientific findings or other information relating to or including the Licensed
Technologies; and (iii) all right, title and interest in and to the Licensed Technologies not expressly granted in Section 3.1 or any Technology Addendum. [***]. 

 

	 	(b)	 This Agreement does not confer any right, title or interest, including any license or rights by implication,
estoppel or otherwise, in tangible or intangible property rights, including any patents, know-how or other inventions or discoveries, that are not explicitly granted to Licensee in Article 3, and OHSU
expressly retains those rights. 

  

	 	(c)	 Patent exhaustion will not apply for any unauthorized sale, and Licensee will provide notice of the Field of
Use restrictions to all entities, including Sublicensees and customers to prevent exhaustion of the Patent Rights and any implied license. 

  

	3.5	 Government Rights. OHSU may have obtained and may in the future obtain funding from an agency of the
U.S. Government. All rights granted under this Agreement which incorporates each Technology Addendum and Material Transfer Addendum, are subject to the rights of and obligations to the U.S. Government, and Licensee agrees to comply and enable OHSU
to comply therewith, including as set forth in 35 U.S.C. Section 200 et seq., regarding substantial manufacture of Licensed Products in the U.S.. Licensee shall report to OHSU in writing whether or not Licensee and each of its Sublicensees is a
“small business firm” as defined by the Small Business Administration for the purposes under the Bayh-Dole Act 37 C.F.R. §401.14(a)(5) in each annual report to OHSU. 

 

	4.	 PAYMENTS 

As partial consideration for the rights granted to Licensee under this Agreement, Licensee will pay OHSU the following: 

 

	4.1	 Upfront License Payment. The parties acknowledge and agree that
up-front licensing fees have been received by OHSU from Licensee, pursuant to the Master Exclusive License Agreement (including in connection with Technology Addendums numbered one through ten and no other).
These payments inure to the benefit of Licensee and its Affiliates, successors and assigns, and have satisfied obligations of Licensee under the OHSU Springboard Program. Licensee shall issue to OHSU [***] shares of Licensee common stock in
accordance with that certain Stock Purchase Agreement attached as Appendix F. 

  

	4.2	 Milestone Payments. Licensee will pay OHSU the following amounts within [***] of Licensee or any
Sublicensee achieving each of the following milestones: 

 [***] 

Each milestone payment in Sections 4.2.1-4.2.4 shall be payable once on an Indication-by-Indication basis and no amounts shall be due for subsequent or repeated achievements of such milestone for the same Indication for a Vir Licensed Product. For
clarity, milestone payments shall be payable more than once for each Vir Licensed Product but the maximum total amount payable per Indication for any Vir Licensed Product under Sections 4.2.1-4.2.4, is
$1,275,000.00. 
  

	4.3	 Royalty Payments. On a Vir Licensed
Product-by-Vir Licensed Product and country-by-country basis, during the Royalty Term for
a Licensed Product in the Country of Sale, Licensee will pay 

  

					
	Confidential	  	10	  	

 
OHSU a continuing royalty of [***] of Net Sales of such Vir Licensed Product in such Country of Sale; provided, however, that during any portion of the Royalty Term for such Vir Licensed Product
in such Country of Sale when no Valid Claim of the Patent Rights would, in the absence of a license under the Patent Rights, be infringed by the manufacture, use, sale, offer for sale or import of such Vir Licensed Product in the Country of Sale,
the royalty rate applicable to Net Sales of such Licensed Product in such Country of Sale under this Section 4.3 shall be reduced to [***]. No multiple royalty payments will be payable to OHSU because a Vir Licensed Product may be covered by
more than one patent or patent application included within the Patent Rights or Licensed Products. Royalty payments are due and payable within [***] after the end of the calendar quarter in which the Net Sale occurred and must be accompanied by a
Quarterly Report as more fully described in Section 8.2 below. 
 For Net Sales solely within any of the Least Developed Countries, the
reasonable and documented direct costs to manufacture the Vir Licensed Products involved in such Net Sales (“Costs”) shall be subtracted from the Net Sales for such Least Developed Countries for purposes of calculating the royalties
due to OHSU. 
  

	4.4	 Third Party Royalties. If Licensee is required to pay royalties to a third party in order to sell a Vir
Licensed Product in either the Country of Sale or the Country of Manufacture as [***], Licensee may credit against royalties otherwise required to be paid to OHSU on such Vir Licensed Product [***] of the amount otherwise due and payable to OHSU on
such Vir Licensed Product. 

  

	4.5	 License Maintenance Payments. Beginning on the seventh anniversary of the Effective Date and until the
first Net Sale in a Developed Country of any Vir Licensed Product, Licensee will pay OHSU a license maintenance payment as specified below. 

[***]. 
  

	4.6	 Minimum Royalty Payments. Commencing on the first January 1 to occur after the first Net Sale of
any Vir Licensed Product in a Developed Country, and for each year thereafter, Licensee will pay to OHSU minimum annual royalties of [***]. OHSU will credit payment of minimum royalties received against any subsequent royalty payments made by
Licensee for any Vir Licensed Products, but only for the year in which the minimum annual royalty was received. Minimum annual royalties are not due on a Vir Licensed
Product-by-Vir Licensed Product basis, but instead the single minimum annual royalty payment per year is creditable against any subsequent royalty payments made by
Licensee for all Vir Licensed Products sold during that year. 

  

	4.7	 Sublicensee Payments. On a
Sublicense-by-Sublicense basis, Licensee will pay OHSU the percentage set forth below of all Sublicense Revenue within [***] of receipt of such applicable Sublicense
Revenue. Licensee will notify OHSU in advance of making any deductions to Sublicense Revenue per this Agreement and Licensee must (i) provide OHSU with adequate accounting and justification in an acceptable form to OHSU and (ii) obtain
OHSU’s written approval for any such deduction to Sublicense Revenue, which shall not be unreasonably withheld by OHSU. 

[***] 
 For the avoidance of
doubt, Sublicensing Revenue shall be determined on a Vir Licensed Product-by-Vir Licensed Product basis and the amount due under this Section 4.7 for any

  

					
	Confidential	  	11	  	

 
Sublicense shall be determined on the basis of its stage of development at the time the Sublicense is granted (e.g. if Vir Licensed Product [***], then Sublicense Revenue shall be calculated
based on the amount due per 4.7.1). If any given Sublicense includes multiple Vir Licensed Products, each at different stages of development, then the percentage of Sublicense Revenue due for such Sublicense shall be determined by the most developed
Vir Licensed Product at the time the Sublicense is granted (e.g. if one Vir Licensed Product [***] and one Vir Licensed Product has [***], then Sublicense Revenue shall be calculated based on the amount due per 4.7.2 rather than 4.7.1). 

 

	4.8	 Material Licensee Fee. Licensee shall pay OHSU all fees described in each Material Transfer Addendum for
the transfer of Licensed Materials contained therein. 

  

	4.9	 Payment Terms. 

 

	 	(a)	 Any payments in a Technology Addendum may be in addition to and/or supersede the payments in this Agreement.

  

	 	(b)	 Except as expressly provided in Section 4.6, all payments are nonrefundable and noncreditable, and due and
payable to OHSU by Licensee on the date specified in this Agreement. In the event no date is specified, payment is due within [***] from the date of the invoice. 

 

	 	(c)	 Any unpaid invoices or payments will incur a late fee of [***] per month ([***] per annum) until paid.
Acceptance of late payments does not negate or waive OHSU’s right to seek any other remedy in law, equity or otherwise. 

  

	 	(d)	 All amounts payable to OHSU under this Agreement are payable in United States dollars, including royalties
based on Net Sales in foreign countries and sublicensee payments payable by Sublicensees located in foreign countries. 

  

	 	(e)	 United States dollar amounts will be calculated using the foreign exchange rate published in The Wall Street
Journal in effect for that foreign currency on the last business day of the reporting period to which the payment relates, and all fees in connection with making the payment will be borne by Licensee. 

 

	 	(f)	 Licensee will [***] by Licensee and Sublicensees. 

 

	 	(g)	 All amounts payable to OHSU under this Agreement are net of all taxes and other charges, and Licensee will be
responsible for paying all taxes, fees and other charges levied by any taxing authority on account of license payments, royalties or any other sums payable under this Agreement. Licensee will deliver copies of all official tax receipts.

  

	 	(h)	 All payments required under this Agreement will be delivered by hand, by overnight courier, by wire transfer,
or by first class, registered or certified mail, properly addressed to OHSU at the address listed in Section 16.1 below. 

  

	 	(i)	 All payments required under Technology Addendums one through fifteen
(1-15) are superseded by this Second Revised and Restated Master Exclusive License Agreement and are no longer due and payable under each Technology Addendum. 

  

					
	Confidential	  	12	  	

	5.	 SUBLICENSING 

  

	5.1	 Method of Granting a Sublicense. Subject to the terms and conditions of this Agreement and
Licensee’s compliance therewith, Licensee may grant Sublicenses through multiple tiers under this Agreement or any Technology Addendum or any Material Transfer Addendum (if the applicable Material Transfer Addendum allows for the grant of a
Sublicense to the respective Licensed Materials) to Sublicensees by entering into a written Sublicense (a) that names OHSU as a third party beneficiary; and (b) is consistent with all terms and conditions of this Agreement applicable to a
Sublicensee, including Sections 7 (Restrictions), 8 (Books, Records and Reports), 9 (Confidential Information), 12 (Representations, Warranties and Disclaimers) and 14 (Indemnification). If a Sublicensee wishes to continue to practice any Licensed
Technology after the termination of this Agreement or any Technology Addendum, OHSU may, without obligation, enter into a separate license agreement with such Sublicensee on terms and conditions no less favorable to OHSU than the terms and
conditions of this Agreement and Technology Addendums. Notwithstanding to the foregoing, OHSU agrees that Licensee may exercise its license rights hereunder through third party service providers, and contract research organizations, in which case
the obligations of this Section and Section 5.2 shall not apply. 

  

	5.2	 Duty to Deliver a Copy of the Sublicense Agreement to OHSU. Within [***] after the execution of each
Sublicense and any amendment thereof, Licensee will deliver to OHSU a copy of that Sublicense and/or amendment to OHSU. 

  

	5.3	 Liability. Licensee remains liable for Sublicensee’s compliance with the terms and conditions of
this Agreement, and OHSU has the right to audit Sublicensee’s compliance. 

  

	6.	 COMMERCIALIZATION 

 

	6.1	 Diligence. Licensee will use Reasonably Diligent Efforts to Develop and Commercialize Vir Licensed
Products as soon as practicable consistent with reasonable business practices and judgment and any obligations to the U.S. government specified in Section 3.5, including: 

[***] 
 Licensee may [***] and any
such [***] will replace the corresponding diligence target(s) in this Section unless [***] of the submission of the Commercial Development Plan Update that it does not approve of one or more of the revisions contained in the Commercial Development
Plan Update. OHSU shall not unreasonably withhold approval of any such revisions. Additional diligence benchmarks may be included in each Technology Addendum. 
  

	6.2	 Commercial Development Plan Update. Furthermore, Licensee will perform substantially as described in the
Commercial Development Plan and submit to OHSU within [***] after the end of each calendar year an updated Commercial Development Plan that includes the information substantially in the form attached as Appendix B and addresses Development plans for
all Vir Licensed Products, certified as accurate by an officer of Licensee, and reasonably acceptable to OHSU. 

  

					
	Confidential	  	13	  	

	7.	 RESTRICTIONS 

  

	7.1	 Compliance with Laws. 

 

	 	(a)	 Licensee is subject to all United States laws and regulations, including the Export Administration Act of 1979
and the Arms Export Control Act (collectively, the “Export Acts”) that control the export of technical data, computer software, laboratory prototypes, Licensed Material, biological materials and other commodities. The transfer of
those items may require a license from the U.S. Government or written assurances by Licensee that it will not export such items to certain foreign countries without prior approval from the U.S. Government. OHSU neither represents that a license is
required, nor that if required, it will be issued. 

  

	 	(b)	 Licensee will at all times and at its expense (i) comply with the Export Acts and obtain all required
export licenses and approvals necessary; (ii) register and give the required notice of this Agreement in each country where an obligation exists; and (iii) be solely responsible for ensuring that Licensee’s performance, the Licensed
Technology, Licensed Materials, and the Vir Licensed Products comply with all applicable laws, rules, regulations, orders, decrees, judgments and other governmental acts of any foreign governmental authorities having jurisdiction over Licensee or
any Sublicensee (including any health and safety rules and regulations and any patent, copyright, trademark or other infringement laws). 

  

	7.2	 No Endorsement/Use of OHSU’s Name. 

 

	 	(a)	 Licensee agrees that it is a startup of OHSU and as such the Parties agree that a press release was released
noting this fact. 

  

	 	(b)	 At Licensee’s request, the parties will issue a joint press release regarding the existence of the
Agreement in a form reasonably acceptable to both parties. Neither Party will use the name, image, trade or service marks, landmarks, monuments, likeness, logos or any other distinguishing feature of the other Party or any employee of the other
Party in any press release, general publication, advertising, marketing, promotional or sales literature (“Releases”), in each case without the prior written consent of the other Party. Once such consent has been made, the Parties
agree that each shall have the right to use any information contained therein for future Releases. OHSU has the right to state that Licensee and Sublicensees are licensed under the Licensed Technology. At OHSU’s request and approval of each use
prior thereto and to the extent permitted by applicable law, Licensee will include the following statement in its advertising of Vir Licensed Products: “Invented at and licensed by Oregon Health & Science University.”

  

	 	(c)	 Notwithstanding anything to the contrary, OHSU does not directly or indirectly endorse any product or service
provided, or to be provided, by Licensee and/or Sublicensees including the Vir Licensed Product. Licensee will not state or imply any endorsement by OHSU or any of its employees. 

 

	7.3	 Marking. Licensee will mark, and cause each Sublicensee to mark, all Vir Licensed Products (or their
packaging or websites) with notices of the Patent Rights and of the conditional license that are customary in the field and that are necessary to enable the Patent Rights to be enforced to their full extent in any country where the Vir Licensed
Products are made, used, sold or imported. Licensee will provide evidence of proper marking upon request by OHSU. 

  

					
	Confidential	  	14	  	

	8.	 BOOKS, RECORDS AND REPORTS 

 

	8.1	 Notice of First Commercial Transfer. Licensee will notify OHSU of the first transfer for commercial
purposes of each Vir Licensed Product in each country in the world within [***] of each such date. 

  

	8.2	 Quarterly Reports. Commencing on first commercial transfer of any Vir Licensed Product, Licensee will
deliver to OHSU within [***] after the end of each calendar quarter (each, a “Reporting Period”) a written report substantially in the form attached as Appendix C that has been signed by an authorized official of Licensee. Each
report will set forth a full accounting of any amounts due to OHSU, including the information necessary or desirable to calculate the amount of (a) the continuing royalty payments due under Section 4.3 above for the Reporting Period on a country-by-country basis; (b) the licensing remuneration received during the Reporting Period, or if there were no gross sales/Net Sales or licensing revenue, Licensee
will provide a short written statement to OHSU stating that fact; (c) any minimum royalties available as a credit for the Reporting Period; and (d) either the amount due to OHSU for the Reporting Period or the amount of any prepaid minimum
royalties that remain available as a credit to Licensee and that will be carried forward to the next Reporting Period. 

  

	8.3	 Books and Records. Licensee will keep proper, continuous and complete books and records of account in
accordance with accounting practices generally accepted in the United States. Those books and records will accurately reflect the sales upon which the continuing royalty payments are based and all other information necessary for the accurate
determination of all payments required under this Agreement. Licensee will retain those books and records for at least five years following their creation. 

  

	8.4	 Audits. Upon reasonable written notice, OHSU will have the right to copy, inspect and audit the records
and books of Licensee and Sublicensees a maximum of once each calendar year during normal business hours for the purpose of verifying the correctness of the payments required under this Agreement. Examination of the books and records for any
Reporting Period will not take place more than five years following the end of that Reporting Period. Licensee will, within [***] Licensee receives notice of the amount of any shortfall, pay OHSU that shortfall, plus all applicable late fee charges
as described in Section 4.9(b), plus interest at [***] above the prime rate of interest set forth in The Wall Street Journal on the date of the shortfall notice. The costs and expense of any such audit will be borne by OHSU unless the
audit discloses that Licensee underpaid by [***] or more during any Reporting Period, in which case, Licensee will pay the costs and expense of the audit. 

  

	9.	 CONFIDENTIAL INFORMATION 

 

	9.1	 Recipient of Confidential Information will protect and keep that Confidential Information secret and
will not (a) disclose that Confidential Information to any person other than to Recipient’s and its actual or prospective Sublicensee’s members, employees, consultants, investors, acquirers, collaborators, agents and independent
contractors with a need to know the Confidential Information to exercise its rights and/or perform its obligations hereunder, and who have agreed to an obligation of confidentiality and prohibition on use at least as protective of the Confidential
Information as this Section 9; or (b) use that Confidential Information for any purpose other than to exercise its rights and perform its obligations under this Agreement. Recipient’s obligations under Section 9 expire five years
following the later of the expiration or termination of this Agreement. 

  

					
	Confidential	  	15	  	

	9.2	 If Licensee provides Confidential Information to OHSU, it must do so solely through the authorized
representative of OHSU designated in Section 16.1. 

  

	9.3	 If Recipient is required by law, including Oregon Public Records Law, regulation or court order to
disclose any of the Confidential Information, it will: (a) promptly notify the Disclosing Party; (b) reasonably assist the Disclosing Party to obtain a protective order or other remedy of Disclosing Party’s election; (c) provide
Disclosing Party prior review of any disclosure; (d) only provide that portion of the Confidential Information that is legally required; and (e) make reasonable efforts to obtain reliable assurance that the Confidential Information will be
maintained in confidence. 

  

	9.4	 Given the nature of the Confidential Information and the damage that would result to the Disclosing
Party upon unauthorized disclosure, use or transfer of their Confidential Information to any third party, the Parties agree that monetary damages would not be a sufficient remedy for any breach or threatened breach of this Section 9. In
addition to all other remedies, Disclosing Party will be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Section 9. The breaching Party agrees to waive any
requirement for the securing or posting of any bond or the showing of actual monetary damages in connection with such remedy hereunder. 

  

	10.	 PROSECUTION, DEFENSE AND MAINTENANCE OF PATENTS 

 

	10.1	 Prosecution and Maintenance. 

Following consultation with OHSU on a patent-by-patent basis,
Licensee will have the right (a) to file, prosecute, maintain and defend; (b) to institute, defend and conduct all interferences and/or oppositions of any patents or patent applications included within the Patent Rights. Licensee will
consult with OHSU on all material patent matters regarding the Patent Rights, and use reasonable good faith efforts to implement all reasonable requests made by OHSU with regard to such matters. Further, Licensee will promptly provide OHSU with
copies of all material written communications to and from any patent office with respect to the patent applications and patents contained in the Patent Rights. Licensee will not abandon the prosecution of any patent application or abandon or
discontinue the maintenance of any patent or patent application included in the Patent Rights without the prior written notification to OHSU. Licensee will give OHSU at least [***] prior written notice of its intent to abandon the prosecution of any
patent application or to discontinue the maintenance of any patent or patent application included in the Patent Rights at which time OHSU will be responsible for prosecution of the patent application or maintenance of the patent if it chooses to
continue prosecution or maintenance of the patent. If Licensee is in default of this Agreement or any Technology Addendum and a [***] cure period for such default has expired, or if Licensee has not fully reimbursed OHSU for all Patent Costs, then
OHSU may assume, at its discretion and with written notice to Licensee, responsibility for the prosecution and maintenance of the Patent Rights. Licensee will cooperate in the transfer of prosecution and maintenance of the Patent Rights to OHSU as
rapidly as practicable and at Licensee’s expense. Prior to Licensee (i) entering liquidation, (ii) having a receiver or administrator appointed over any assets related to this Agreement, (iii) making any voluntary assignment with
or for the benefit of any of its creditors, (iv) ceasing to carry on business, or any similar event under the law of any foreign jurisdiction, OHSU shall assume, at its discretion, responsibility for the prosecution and maintenance of the
Patent Rights and Licensee will transfer the prosecution and maintenance of the Patent Rights to OHSU immediately at Licensee’s expense. 

  

					
	Confidential	  	16	  	

	10.2	 Reimbursement of Ongoing Patent Costs. Licensee agrees to reimburse OHSU for Patent Costs as specified
within each Technology Addendum unless Licensee has surrendered its rights under Section 10.4 below. 

  

	10.3	 Cooperation and Disclosure. Licensee will promptly inform OHSU of all matters that come to its attention
that may affect the preparation, filing, prosecution, defense or maintenance of the Patent Rights. Licensee has a continuing responsibility to keep OHSU informed of its and all Sublicensees’ entity status, including any change from
“small” to “large” entity (as defined by the United States Patent and Trademark Office). 

  

	10.4	 Loss of Rights. If Licensee elects not to pay the Patent Costs for the filing, prosecution, defense
and/or maintenance of any patent application or patent on a worldwide basis, then such patent or patent application will be excluded from the term “Patent Rights” and all rights relating to such patent application or patents will revert to
OHSU without further obligation to Licensee and may be freely licensed by OHSU to others. 

  

	10.5	 Patent Term Extension. The Parties will cooperate in selecting a patent within the Patent Rights to seek
a term extension for or supplementary protection certificate under in accordance with the applicable laws of any country, provided that Licensee shall have the right to select the patent for any patent term extension. Each Party agrees to execute
any documents and to take any additional actions as the other Party may reasonably request in connection therewith. 

  

	10.6	 Challenge. In the event Licensee intends to challenge the validity or enforceability of any of
the Patent Rights, Licensee will (a) give OHSU [***] prior written notice; (b) continue to make all payments required hereunder directly to OHSU without the right to pay into escrow or other account any such amounts; (c) [***]; and (d)
[***] if such Patent Rights is/are held valid and enforceable. For purposes of clarity, Licensee agrees that no payment made to OHSU is refundable or may be offset, including any amounts paid under this Agreement prior to or during the period of the
challenge, even if the challenge is successful or it is otherwise determined that the Patent Rights do not include valid claims. For clarity, this section does not include any Know-How. 

 

	11.	 PATENT ENFORCEMENT 

 

	11.1	 Enforcement Rights. If either OHSU or Licensee becomes aware of any actual or threatened infringement of
any Licensed Technology, that Party will promptly notify the other of each infringement or possible infringement, as well as any facts that may affect the validity, scope or enforceability of the Patent Rights (the “Infringement
Notice”). The Parties will reasonably cooperate with each other to abate that infringement without litigation. 

  

	 	(a)	 If within [***] after the date of the Infringement Notice, attempts to abate such infringement are
unsuccessful, then Licensee shall have the first right to bring an action to enforce the Patent Rights in the Field of Use at its own expense, provided Licensee first notifies OHSU and carefully considers OHSU’s views before initiating and
throughout that suit. In that case, OHSU will cooperate with Licensee as reasonably requested, at Licensee’s expense, and may be named as a nominal party plaintiff to support such enforcement action. 

  

					
	Confidential	  	17	  	

	 	(b)	 If Licensee fails to bring an action within [***] after the date the Infringement Notice, OHSU may bring an
action at its own expense, in which case Licensee will cooperate with OHSU, including joining the suit as reasonably requested, at OHSU’s expense. 

The Party initiating and maintaining the action will keep the other Party reasonably apprised of the status and progress of the litigation.

  

	11.2	 Fees and Costs. In any infringement action brought under Section 11.1(a), Licensee will pay [***].

  

	11.3	 Settlement and Recovery. 

 

	 	(a)	 Licensee agrees OHSU owns the Licensed Technologies, and Licensee will not settle any action or other
proceeding in any manner that includes an admission of fault and/or is prejudicial to OHSU, including any of the rights regarding the Licensed Technologies, without OHSU’s prior written approval. 

 

	 	(b)	 Any recovery made by either Party, through court judgment or settlement, will be applied first to [***], and
second, to [***]. However, Licensee shall not be required to reimburse OHSU for royalties that it would have received beyond the total amount that Licensee receives through court judgment or settlement. [***]. Should OHSU be made a Party to any suit
described in Section 11.1(a), [***] as a result of and in opposing that action. 

  

	12.	 REPRESENTATIONS, WARRANTIES AND DISCLAIMERS 

 

	12.1	 Mutual Representations and Warranties. Each Party represents and warrants to the other that (a) it
is and will be at all times during the Term a valid legal entity existing under the law of its state of incorporation with the power to own all of its properties and assets and to carry on its business as it is currently being conducted; and
(b) the execution and delivery of this Agreement has been duly authorized and no further approval, corporate or otherwise, is required in order to execute this binding Agreement. 

 

	12.2	 Disclaimers. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY NOT EXPRESSLY SET FORTH IN SECTION 12.1,
AND EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE, COURSE OF DEALING, USAGE, AND TRADE PRACTICE, WITH RESPECT TO THE SCOPE,
VALIDITY OR ENFORCEABILITY OF THE LICENSED TECHNOLOGIES; THAT ANY PATENT WILL ISSUE BASED UPON ANY OF THE PENDING PATENT RIGHTS; OR THAT THE MANUFACTURE, USE, SALE, OFFER FOR SALE OR IMPORTATION OF ANY LICENSED PRODUCTS WILL NOT INFRINGE PROPERTY
RIGHTS. IN NO EVENT WILL OHSU BE LIABLE FOR LOSS OF PROFITS, LOSS OF USE, OR ANY OTHER CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES. NOTHING WILL LIMIT OHSU’S REMEDIES OR ABILITY TO RECOVER DAMAGES IN THE EVENT OHSU ASSERTS ITS
INTELLECTUAL PROPERTY RIGHTS, INCLUDING INCREASED DAMAGES FOR WILLFUL INFRINGEMENT. 

  

	12.3	 Prohibition Against Inconsistent Representations. Licensee will not make any statements, representations
or warranties, or accept any liabilities or responsibilities whatsoever which are inconsistent with any term or condition of this Agreement. 

  

					
	Confidential	  	18	  	

	12.4	 Licensed Material Disclaimer of Warranties and Obligations. Any Licensed Materials delivered pursuant to
this Agreement are understood to be experimental in nature and may have hazardous properties. OHSU makes no representations whatsoever (a) with regard to the scope, accuracy, completeness or usefulness of the Licensed Materials; (b) that
the Licensed Materials can be exploited without infringing other patents or other intellectual property rights of third parties; or (c) that the Licensed Materials will accomplish any particular results or are safe or fit for any purpose. OHSU
expressly disclaims the warranties of merchantability, fitness for a particular purpose, exclusivity or results obtained from use of Licensed Materials. 

  

	12.5	 Licensed Materials Limitation of Liability. In no event will OHSU be liable for any incidental,
consequential, special or punitive damages resulting from the use of the any Licensed Materials or Clinical Materials. Unless prohibited by law, Licensee assumes all liability for claims for damages against it and/or OHSU by third parties which
arise from the use, storage, transfer, sale, offer for sale, sell, import, or disposal of the Licensed Materials and/or Clinical Material by Licensee, Affiliates, any Sublicensee or third party service providers acting on behalf of Licensee or its
Affiliates or any Sublicensee. 

  

	13.	 INSURANCE 

  

	13.1	 Licensee will maintain general and product liability insurance with deductibles and minimum limits of
liability in amounts commensurate with industry standards and sufficient to satisfy its obligation hereunder, including Section 14.1. Evidence of insurance will be provided to OHSU upon request. 

 

	14.	 INDEMNIFICATION 

 

	14.1	 Licensee will indemnify, defend and hold harmless OHSU, its directors, trustees, officers, employees,
students, fellows, agents, consultants, OHSU Inventors or Inventors who have an obligations to assign to OHSU, the sponsors of the research that led to the Licensed Technologies and/or Licensed Materials (“OHSU Indemnitees”) from
and against all third party claims, liabilities, demands, damages, costs, expenses (including attorney fees and costs) and losses, including (a) for death, personal injury, illness and property damage arising from or relating in any way to this
Agreement, including the Licensed Products, Vir Licensed Products and Licensed Materials and/or Clinical Materials; (b) the use or misuse of the Licensed Technologies, Licensed Products, Licensed Materials and/or Clinical Materials by or on
behalf of Licensee or Sublicensees their customers, suppliers, independent contractors and other third persons; (c) the design, manufacture, distribution, storage, sale, import and/or use of any Licensed Materials and/or Clinical Materials, Vir
Licensed Products, Licensed Products or other products or processes developed in connection with or arising out of the Licensed Technologies; and (d) Licensee’s and/or Sublicensees’ negligence and willful malfeasance. OHSU will
reasonably cooperate with Licensee, at Licensee’s expense, in the defense of such action; provided that under no circumstances will Licensee or any party acting on its behalf make any admissions of fault or impose any material obligation on
OHSU Indemnitees, including with respect to the Licensed Technologies, the Licensed Materials and/or Clinical Materials. 

  

	14.2	 To the extent necessary to satisfy its obligations to OHSU under Section 14.1, Licensee hereby
waives any immunity or exemption from liability for the personal injury or death of its employees that may exist under, or any right to receive contribution from OHSU created by, the workers’ compensation laws of the state where the injury
occurs or the employee is located. 

  

					
	Confidential	  	19	  	

	15.	 TERM AND TERMINATION 

 

	15.1	 Expiration. This Agreement is effective as of the Effective Date and unless sooner terminated under this
Section 15, will expire at the end of the Term. 

  

	15.2	 Termination by Either Party. 

 

	 	(a)	 Either Party may terminate this Agreement, any Technology Addendum and/or any Material Transfer Addendum, if
the other Party commits a breach and fails to remedy such breach within 60 days after receiving written notice (the “Cure Period”). The Cure Period may be extended an additional 120 days (the “Cure Period Extension”) if
the breaching Party is unable to reasonably cure the breach within the Cure Period. Any request for a Cure Period Extension must be submitted to the non-breaching Party during the Cure Period and such request
will be accompanied by a written description detailing why such breach could not be cured during the Cure Period, and will describe in detail, the actions that the breaching party will take to cure the breach during the Cure Period Extension (the
“Cure Plan”). The Cure Plan will be reviewed, approved, and signed by authorized representatives of Parties. If OHSU is unable to determine Licensee’s and its Sublicensee’s compliance with the terms and conditions of this
Agreement, any Technology Addendum, and/or any Material Transfer Addendum because Licensee has not provided sufficient communications required by this Agreement, any Technology Addendum, and/or any Material Transfer Addendum, the Parties agree that
such failure to provide will also be deemed evidence of Licensee’s failure to perform activities to which were to be reported in such communications. 

  

	 	(b)	 This Agreement will terminate if the other Party enters liquidation, has a receiver or administrator appointed
over any assets related to this Agreement, makes any voluntary assignment with or for the benefit of any of its creditors, or ceases to carry on business, or any similar event under the law of any foreign jurisdiction. If either Party enters into
any of the above actions inadvertently, and such Party fails to remedy such inadvertent action within 30 days of such action, then this Agreement, each Technology Addendum and each Material Transfer Addendum will terminate immediately.

  

	15.3	 Licensee’s Termination Rights. At any time following the first anniversary of the Effective Date,
Licensee may terminate this Agreement and/or any Technology Addendum or Material Transfer Addendum by giving OHSU sixty (60) days’ written notice and paying OHSU all appropriate sums then due and payable. 

 

	15.4	 Termination by OHSU. OHSU does not license its rights to entities that bring suit against it and as
such, OHSU may immediately terminate this Agreement if Licensee or any Sublicensees directly or indirectly bring any action or proceeding against OHSU, including any pertaining to tangible or intellectual property, except as described in
Section 10.6, owned by OHSU, unless (a) Licensee or Sublicensee has attempted reasonably and in good faith to resolve the subject matter of such suit through discussion and mediation as described in Section 16.7, or (b) the suit
relates to an uncured material breach of this Agreement by OHSU that has not been resolved in accordance with this Agreement or (c) by way of counterclaims or cross claim. 

 

	15.5	 Consequences of Termination of Technology Addendum or Material Transfer Addendum. Upon the termination
of a specific Technology Addendum or a Material Transfer Addendum under Section 15.3 (“Terminated Addendum”), all rights licensed or transferred by OHSU to Licensee under Terminated Addendum will revert to OHSU, all Sublicenses
will terminate under 

  

					
	Confidential	  	20	  	

	 	
such Terminated Addendum. In the case where Licensee has had direct responsibility for prosecution and maintenance of the Patent Rights under such Terminated Addendum, Licensee shall do
everything necessary to revert patent prosecution back to OHSU at Licensee’s expense. 

  

	15.6	 Consequences of Expiration/Termination. Upon expiration or earlier termination of this entire Agreement
for any reason whatsoever: 

  

	 	(a)	 All Technology Addendums and Material Transfer Addendums shall terminate; 

 

	 	(b)	 Upon termination, but not expiration, of this Agreement for any reason whatsoever, Licensee’s rights to
Licensed Products will immediately terminate, and its Sublicensees rights to Licensed Products will immediately terminate; provided that if Licensee or any Sublicensee then possess, have started the manufacture of or have accepted binding orders for
Vir Licensed Products, then Licensee or such Sublicensee shall maintain its right to sell their inventories, complete the manufacture of, and market and sell the finished Vir Licensed Products to the extent necessary to dispose of those inventories
and fill those orders, subject at all times to Licensee’s obligation to comply with the terms and conditions of this Agreement, including to pay OHSU the payments under Section 4 and to deliver the reports required in Section 8.2;

  

	 	(c)	 Neither Party will be discharged from any liability or obligation to the other Party that arose, accrued or
became due before the effective date of expiration or termination; 

  

	 	(d)	 Within [***] after the expiration or earlier termination of this Agreement for any reason, Licensee will submit
a final report in form and content similar to the Quarterly Report and pay all amounts required to be paid to OHSU under this Agreement, including the prorated minimum annual license maintenance payment and minimum annual royalty payments;

  

	 	(e)	 Sections that by their nature prescribe continuing rights and obligations will survive until their purposes are
fulfilled, including Section 7 (Restrictions), 8 (Books, Records and Reports), 9 (Confidential Information), 12 (Representations, Warranties and Disclaimers), 13 (Insurance), 14 (Indemnification) and 16 (General Provisions);

  

	 	(f)	 Upon any termination, but not expiration, of this Agreement, Licensee will return to OHSU all Licensed
Technology materials including all manufactured materials containing Licensed Products, books, records, lab data, manufacturing data and protocols, and Licensed Materials; 

 

	 	(g)	 Each Party will promptly return or destroy the Confidential Information of the other Party (except that each
Party may retain one copy of the other Party’s Confidential Information solely for archival purposes), and will deliver a certificate signed by one of its authorized officers that it has done so; and 

 

	 	(h)	 All rights licensed or transferred by OHSU to Licensee under this Agreement will revert to OHSU, all
Sublicenses will terminate; provided that in the case of expiration of this Agreement, Licensee shall have under any Know-How, Licensed Technology, and Licensed Material a fully
paid-up, worldwide, non-exclusive license to conduct research and to develop, make, have made, use, sell, offer for sale and import Licensed Products and Vir Licensed
Products in the Field of Use. In the case where Licensee has had direct responsibility for prosecution and maintenance of the Patent Rights, Licensee shall do everything necessary to revert patent prosecution back to OHSU at Licensee’s expense.

  

					
	Confidential	  	21	  	

	16.	 GENERAL PROVISIONS 

 

	16.1	 Notices. All notices or other communications given hereunder shall be in writing, shall be signed by an
officer of the Party sending such notice or other communication, and shall be delivered by hand, by overnight courier, by electronic mail or by facsimile with all delivery charges prepaid and addressed to the Parties as follows:

  

			
	 If to OHSU:
	  	 [***]

	 If to Licensee:
	  	 [***]

 Communications under Sections 10 and 11 may also be made by verbal disclosure in person and/or
telephonically. All such notices and communications will be effective on the date delivered, if in person or telephonically, on the date of the postmark of that notice or communication if by courier, and on the date of the date stamp of that notice
or communication if by electronic mail or facsimile. Either Party may change its address by giving notice of that change to the other Party. 
  

	16.2	 Waivers. Neither Party will be deemed to have waived any of its rights under this Agreement until it has
signed a written waiver of those rights. Without limiting the preceding, no failure or delay by either Party in exercising any rights, powers or remedies under this Agreement will operate as a waiver of any such right, power or remedy, and no waiver
will constitute a waiver of any other provision, breach, right or remedy, nor will any waiver constitute a continuing waiver or be effective except for the specific instance and for the specific purpose given. 

 

	16.3	 Amendments. If either Party wishes to modify this Agreement or any Technology Addendum or any Material
Transfer Addendum, the Parties will confer in good faith to determine the desirability of such modification. No modification will be effective until a written amendment is signed by both Parties. 

 

	16.4	 Assignment. Except upon the sale, assignment or transfer, of all assets of Licensee related to this
Agreement to a third party, Licensee will not assign or transfer its interests in nor delegate its obligations under this Agreement or any Technology Addendum or Material Transfer Addendum, whether by transfer, merger, operation of law or otherwise
without OHSU’s written consent, which will not be unreasonably withheld. A Change of Control of Licensee (voting or otherwise) will be deemed an assignment for purposes of this Section 16.4. This Agreement will be binding on and inure to a
Party’s successors and assigns. OHSU has the right to assign its Licensed Technologies and this Agreement to any successor or assign. Licensee shall notify OHSU of any assignments or transfers within a reasonable time period of such action
being finalized. 

  

	16.5	 Governing Law; Jurisdiction and Venue. This Agreement will be governed by and construed in accordance
with the laws of the State of Oregon without reference to any choice of law provisions, the Uniform Commercial Code or the International Convention on the Sale of Goods. Subject to Section 16.7, any claim, action or suit between OHSU and
Licensee and/or Sublicensee that arise out of or relate to this Agreement and that is not barred by sovereign immunity will be brought and conducted solely and exclusively within the Circuit Court for Multnomah County, Oregon, provided however, if
any such claim, action or suit may be brought 

  

					
	Confidential	  	22	  	

	 	
only in a federal forum or pertains to the enforcement of the Patent Rights, and does not waive sovereign immunity on behalf of OHSU unless OHSU so elects at that time, such claim, action or suit
will be brought and conducted solely and exclusively within the United States District Court of Oregon and licensee and/or Sublicensee consents to the jurisdiction of and venue in those courts. Nothing herein will be construed as a waiver of
sovereign immunity. 

  

	16.6	 Severability. The terms and conditions of this Agreement are severable. If any term or condition of this
Agreement is rendered invalid or unenforceable by any law or regulation, or declared null and void by any court of competent jurisdiction, that part will be reformed, if possible, to conform to law, and if reformation is not possible, that part will
be deleted in such jurisdiction only and the remainder of the terms and conditions of this Agreement as well as the invalid or unenforceable term or condition in all jurisdictions where valid and enforceable will remain in full force and effect,
unless enforcement of this Agreement without the invalid or unenforceable term or condition would be grossly inequitable under the circumstances or would frustrate the primary purpose of this Agreement. 

 

	16.7	 Dispute Resolution. The Parties agree to first attempt to settle amicably any controversy or claim
arising out of or relating to this Agreement by providing copies of documents reasonably requested to enable a Party to evaluate its position. If the Parties are unable to settle amicably any controversy or claim then both Parties agree that all
disputes between them arising out of or relating to this Agreement will be submitted to non-binding mediation unless the Parties mutually agree otherwise in writing. Licensee further agrees to include a
similar provision in all agreements with Sublicensees thereby providing for mediation as the first and primary method for dispute resolution between the parties to those agreements. All parties agree to exercise their best effort in good faith to
resolve all disputes in mediation provided, however, nothing will limit OHSU’s remedies or ability to enforce its rights in the Licensed Technology in any jurisdiction or manner. 

 

	16.8	 Independent Contractor; No Agency. Neither Party will be deemed to be the employee, representative,
agent, joint venture or partner of the other Party for any purpose. Neither Party has the authority to obligate or bind the other, or to incur any liability on behalf of the other, nor to direct the employees of the other. 

 

	16.9	 Interpretation. Both Parties have had the opportunity to have this Agreement and each Technology
Addendum and/or Material Transfer Addendum reviewed by their attorneys. Therefore, no rule of construction or interpretation that favors or disfavors either Party will apply to the interpretation of this Agreement including each Technology Addendum
and/or Material Transfer Addendum. Instead, this Agreement and each Technology Addendum and/or Material Transfer Addendum will be interpreted according to the fair meaning of its terms. The captions or headings of this Agreement and each Technology
Addendum and/or Material Transfer Addendum are for convenience of reference only. They will not limit or otherwise affect the meaning or interpretation of any provision of this Agreement and each Technology Addendum and/or Material Transfer
Addendum. The words “includes” and “including” are not limited in any way and mean “includes or including without limitation.” The word “person” includes individuals, corporations, partnerships, limited
liability companies, co-operatives, associations and other natural and legal persons. The term “and/or” means each and all of the persons, words, provisions or items connected by that term; i.e., it
has a joint and several meaning. The word “will” is a synonym for the word “shall”. All attachments to this Agreement and each Technology Addendum and/or Material Transfer Addendum are a part of and are incorporated in this
Agreement. 

  

					
	Confidential	  	23	  	

	16.10	 Counterparts; Facsimile Delivery. This Agreement and each Technology Addendum and/or Material Transfer
Addendum may be executed in one or more counterparts, each of which will be deemed an original and all of which together will constitute one and the same Agreement. This Agreement and each Technology Addendum and/or Material Transfer Addendum may be
delivered by facsimile, and when so delivered will have the same force and effect as delivery of an original signature. 

  

	16.11	 Entire Agreement. With respect to the Licensed Technologies, this Agreement, including its Appendices,
Technology Addendums, and Material Transfer Addendums are incorporated herein by reference, is the entire agreement between the Parties and supersedes all prior discussions, representations, warranties and agreements, both written and oral between
the Parties, including but not limited to the Master Exclusive License Agreement effective June 22, 2012 and the Revised and Restated Master Exclusive License Agreement executed on August 18, 2014. 

 

							
	 OHSU:
 OREGON
HEALTH & SCIENCE UNIVERSITY
	  	
			
	 /s/Andrew R.O. Watson

Andrew R.O. Watson, PhD, CLP
 Director, Technology
Transfer
	 		  	 August 27, 2019

Date

			
	 LICENSEE:
 VIR BIOTECHNOLOGY,
INC.
	 		  	
				
	By:	 	 /s/Jay Parrish

Signature of Authorized Official
	 		  	 August 27, 2019

Date

							
				
	Name:	 	 Jay Parrish
	 		  	

							
				
	Title:	 	 Chief Business Officer
	 		  	

  

					
	Confidential	  	24	  	

 APPENDIX A 

COMMERCIAL DEVELOPMENT PLAN 
 [***] 

  

					
	Confidential	  	25	  	

 APPENDIX B 

FORM OF ANNUAL UPDATE TO THE COMMERCIAL DEVELOPMENT PLAN 

To: Oregon Health & Science University (“OHSU”) 

From:
                                    
(“Licensee”) 
 Date:
                                      

Period Covered by Report: January 1, 20     through December 31, 20    
(the “Reporting Period”). 
 This Annual Update to the Commercial Development Plan Report (this
“Report”) is provided by Licensee to OHSU pursuant to their Exclusive License Agreement dated
                             regarding Invention Disclosure No(s)
         (the “Agreement”). 
 1.    A
copy of Licensee’s Commercial Development Plan in effect for the Reporting Period covered by this Report is attached to this Report as Exhibit A (the “Current Plan”). 

2.    [***]. 

3.    A copy of Licensee’s updated Commercial Development Plan, including the anticipated date of first
transfer of Vir Licensed Product for commercial purposes if such transfer has not been made as of the date of this Report, is attached to this Report as Exhibit C (the “New Plan”). 

4.    A listing of any new investigational new drug (IND) application(s) filed on Vir Licensed Products in the past
year with information on which Patent Rights the Licensee believes covers such Vir Licensed Product. 

5.    [***]. 

This Report is true, accurate and complete in all material respects. 

 

					
		 	  

[must be signed and dated by officer of Licensee]
	 	

  

					
	Confidential	  	26	  	

 APPENDIX C 

FORM OF QUARTERLY REPORT 
  

							
	Name of Licensee:	 	  
	  	                Invention Disclosure #	 	  

				
	Reporting Period:	 	  
	  		 	

  

	A.	 Royalties 

[***] 
  

	B.	 Milestone payments 

  

	C.	 License maintenance payments 

 

	D.	 Sublicensee payments 

[***] 
 THE INFORMATION IN THIS REPORT IS TRUE, ACCURATE AND
COMPLETE FOR THE REPORTING PERIOD SPECIFIED ABOVE. 
  

					
	LICENSEE:
                                         
       	  	

							
	By:	 	  
	  		  	  

		 	Signature of Authorized Official	  		  	Date

					
	Printed Name	 	  
	  	

					
			
	Title	 	  
	  	

  

					
	Confidential	  	27	  	

 APPENDIX D 

FORM OF THE TECHNOLOGY ADDENDUM 

TECHNOLOGY ADDENDUM NO. [●] TO THE
SECOND REVISED AND RESTATED 
 MASTER
EXCLUSIVE LICENSE AGREEMENT BETWEEN OHSU AND VIR 

BIOTECHNOLOGY, INC. 

This Technology Addendum (this “Technology Addendum”), dated and effective as of [●] (the “Technology Addendum Effective
Date”), is between the Oregon Health & Science University, having offices at 0690 SW Bancroft Street, Portland, Oregon 97239 (“OHSU”), and Vir Biotechnology, Inc., having offices at 499 Illinois Street, San
Francisco, California 94158 (“Licensee”). OHSU and Licensee are herein referred to each as a “Party” and collectively as the “Parties.” 
  

	1	 BACKGROUND 

  

	1.1	 OHSU and Licensee have entered into a Master Exclusive License Agreement dated June 22, 2012 (the
“Agreement”) and subsequently revised and restated on August 18, 2014 and second revised and restated on August 27, 2019. 

  

	1.2	 OHSU has certain inventions and discoveries generally described in OHSU Invention Disclosure [●] entitled
[●] (the “Invention”). 

  

	1.3	 OHSU desires the Invention to be utilized for the public benefit to the fullest extent possible.

  

	1.4	 Licensee intends to bring together the scientific and business talent, facilities and capital to develop and
market products and processes based upon the Invention. 

  

	1.5	 Licensee wishes to obtain from OHSU, and OHSU is willing to grant to Licensee, a license to exploit the
Invention subject to the terms and conditions set forth in the Agreement and set forth below. 

  

	2	 DEFINITIONS 

Capitalized terms used in this Technology Addendum shall have the meaning as set forth in the Agreement unless otherwise stated herein. 

 

	2.1	 “Addendum Term” means the period beginning on the Technology Addendum
Effective Date and, subject to earlier termination under Section 15, will expire upon the Term of the Agreement. 

  

	2.2	 “Know-How” means information, including Confidential
Information, provided by the Inventors at their sole election, as set forth in Appendix A-1, and materials transferred to Licensee in amounts determined solely by Inventors. 

 

	2.3	 “Patent Rights” means the patents and patent applications listed on Appendix B-1 to this Technology Addendum, PCT, U.S. and foreign applications thereon, including continuations, continuations-in-part (but only
to the extent of subject matter therein that is described sufficiently 

  

					
	Confidential	  	28	  	

	 	
in the patents and patent applications listed on Appendix B-1 to satisfy the requirements of 35 U.S.C. §112) and divisionals, patents issuing from any
of the foregoing, and reissues, extensions, supplementary protection certificates, substitute applications, and reexaminations of any of the foregoing. 

  

	3	 GRANT OF RIGHTS 

 

	 	(a)	 Patent License. Subject to the terms and conditions of the Agreement, this Technology Addendum and
Licensee’s compliance therewith, OHSU grants to Licensee and its Affiliates an exclusive worldwide license, with the right to grant Sublicenses as set forth in the Agreement. 

 

	 	(b)	 Non-Exclusive Know-How
License. Subject to the terms and conditions of the Agreement, this Technology Addendum and Licensee’s compliance therewith, OHSU grants to Licensee a nonexclusive, worldwide license, with the right to grant Sublicenses as set forth in the
Agreement. 

  

	4	 PAYMENTS 

As partial consideration for the rights granted to Licensee under this Technology Addendum, in addition to the payments described in the
Agreement, Licensee will pay OHSU the following: 
  

	4.1	 Technology Addendum Issue Fee. 

[To be negotiated for each Technology.] 
  

	4.2	 Other Payments for Technology Addendum 

[To be negotiated for each Technology Addendum.] 
  

	4.3	 Reimbursement of Patent Costs. Within [***] after the Technology Addendum Effective Date, Licensee will
pay OHSU for any Patent Costs (if any) on the Patent Rights incurred by OHSU as of the date of signing of this Technology Addendum. Licensee agrees to reimburse OHSU for all additional Patent Costs incurred on the Patent Rights within [***] of
invoice unless Licensee has surrendered its rights under Section 10.4 of the Agreement. 

  

	5	 COMMERCIALIZATION 

 

	5.1	 Diligence. All within the context of a Vir Licensed Product, Licensee will use Reasonably Diligent
Efforts to Develop and Commercialize Licensed Products as soon as practicable consistent with reasonable business practices and judgment and any obligations to the U.S. government specified in Section 3.5, including Licensee’s obligations
under section 6.1 of the Agreement and/or: 

 [To be completed prior to execution of each Technology Addendum] 

 

	5.2	 Commercial Development Plan. Licensee will perform substantially as described in the Commercial
Development Plan attached as Appendix A to the Agreement. 

  

					
	Confidential	  	29	  	

	5.3	 [Optional language for inventions arising from third party funding, including but not limited to,
funding from the Bill & Melinda Gates Foundation to meet Global Access requirements or other special circumstances.] 

 

	6	 TERM AND TERMINATION 

 

	6.1	 Expiration. This Technology Addendum is effective as of the Technology Addendum Effective Date and
unless sooner terminated in accordance with the Agreement, will expire at the end of the Addendum Term. 

  

	7	 GENERAL PROVISIONS 

 

	7.1	 Entire Agreement. With respect to the Licensed Technology, this Technology Addendum and the Agreement,
including their Appendices which are incorporated herein by reference, is the entire agreement between the Parties and supersedes all prior discussions, representations, warranties and agreements, both written and oral between the Parties.

 OHSU: 
 OREGON HEALTH &
SCIENCE UNIVERSITY 

							
				
	  
	 	                	  	  
	  	                                      
  
	Signature of Authorized Official	 		  	Date	  	

 LICENSEE: 
 VIR
BIOTECHNOLOGY, INC. 
  

									
	By:	 	  
	 	                                	  	  
	 	                            
		 	Signature of Authorized Official	 		  	Date	 	
					
	Name:	 	  
	 		  		 	
					
	Title:	 	  
	 		  		 	

  

					
	Confidential	  	30	  	

 Appendix A-1 

Know-How Technology Addendum 

[To be completed prior to execution of each Technology Addendum] 

  

					
	Confidential	  	31	  	

 Appendix B-1 

Patent Rights Technology Addendum 
 [To
be completed prior to execution of each Technology Addendum] 

  

					
	Confidential	  	32	  	

 APPENDIX E 

FORM MATERIAL TRANSFER ADDENDUM 

MATERIAL TRANSFER ADDENDUM NO. [●] TO
THE MASTER EXCLUSIVE LICENSE 
 AGREEMENT
BETWEEN OHSU AND VIR BIOTECHNOLOGY, INC. 
 This Material Transfer Addendum
(this “Material Transfer Addendum”), dated and effective as of [●] (the “Material Transfer Addendum Effective Date”), is between the Oregon Health & Science University, having offices at 0690
SW Bancroft Street, Portland, Oregon 97239 (“OHSU”), and Vir Biotechnology, Inc., having offices at 499 Illinois Street, San Francisco, California 94158 (“Licensee”). OHSU and Licensee are herein referred to each as
a “Party” and collectively as the “Parties.” 
  

	A.	 OHSU and Licensee have entered into a Master Exclusive License Agreement dated June 22, 2012 (the
“Agreement”) and subsequently revised and restated on August 18, 2014 and on [●]. 

  

	B.	 OHSU has certain Licensed Materials listed in Appendix A-1 of this
Material Transfer Addendum (the “Licensed Materials”). 

  

	C.	 Licensee wishes to obtain from OHSU, and OHSU is willing to grant to Licensee, a license to exploit the
Licensed Materials subject to the terms and conditions set forth in the Agreement and this Material Transfer Addendum. 

 NOW, THEREFORE,
it is hereby agreed as follows: 
  

	1.	 DEFINITIONS 

Capitalized terms used in this Technology Addendum shall have the meaning as set forth in the Agreement unless otherwise stated herein. 

 

	1.1	 “Addendum Term” means the period beginning on the Material Transfer Addendum
Effective Date and, subject to earlier termination under Section 15 of the Agreement, will expire upon the expiration of the Agreement. 

  

	2.	 GRANT OF RIGHTS 

 

	2.1	 Non-Exclusive Material License. Subject to the terms and
conditions of the Agreement, execution of this Material Transfer Addendum and Licensee’s compliance therewith, OHSU grants to Licensee a nonexclusive, [to be completed prior to execution of each Material Transfer Addendum].

  

	3.	 PAYMENTS 

  

	3.1	 Material License Fee. Licensee will pay OHSU a one-time license
fee of [●] ($●) dollars within [***] after of the Material Transfer Addendum Effective Date as partial consideration rights granted under this Material Transfer Addendum in accordance with the Agreement. 

 

	3.2	 Shipping Fees. Shipping fees shall be determined at the time of shipment and Licensee acknowledges that
these fees will be incurred following execution of this Material Transfer Addendum. Licensee shall pay for all such shipping fees and OHSU shall use Licensee’s FedEx Account Number to pay for shipping. 

Licensee FedEx Account Number: __________________ 

  

					
	Confidential	  	33	  	

	4.	 RESTRICTIONS 

  

	4.1	 Use Restrictions. Licensee will not use the Licensed Materials for any purpose other than as allowed in
this Material Transfer Addendum and may not incorporate the Licensed Materials in any product for use in humans, unless allowed under Section 2 of this Material Transfer Addendum, without OHSU’s prior written consent. Licensee agrees to
use the Licensed Materials in compliance with all applicable statutes and regulations, including without limitation those governing disposal of hazardous materials, export control regulations, and any condition of the Agreement.

  

	5.	 ADDITIONAL LICENSEE REPRESENTATION AND WARRANTIES. 

 

	5.1	 [To be completed prior to execution of each Material Transfer Addendum] 

 

	6.	 TERM AND TERMINATION 

 

	6.1	 Expiration. This Material Transfer Addendum is effective as of the Material Transfer Addendum Effective
Date and unless sooner terminated under this Section 6, or as specified in the Agreement, will expire at the end of the Addendum Term. 

  

	7	 GENERAL PROVISIONS 

 

	7.1	 Entire Agreement. With respect to this Material Transfer Addendum and the Agreement, including their
Appendices which are incorporated herein by reference, is the entire agreement between the Parties and supersedes all prior discussions, representations, warranties and agreements, both written and oral between the Parties. 

 

							
	OHSU:	  		  	
	OREGON HEALTH & SCIENCE UNIVERSITY	  	
			
	  
	  		  	  

	Signature of Authorized Official	  		  	Date
			
	LICENSEE:	  		  	
	VIR BIOTECHNOLOGY, INC.	  		  	
				
	By:	  	  
	  		  	  

		  	Signature of Authorized Official	  		  	Date
				
	Name	  	  
	  		  	
				
	Title	  	  
	  		  	

  

					
	Confidential	  	34	  	

 APPENDIX A-1 

LICENSED MATERIALS 
  

					
	 Licensed Material
	  	Access
Fee	 
		  			
		  			
		  			
	 Total Access Fee
	  			

  

					
	Confidential	  	35	  	

 APPENDIX F 

STOCK PURCHASE AGREEMENT 

  

					
	Confidential	  	36

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]